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When you can measure what you are 
speaking about and express it in numbers, you 
know something about it; but when you can 
not measure it, when you cannot express it in 
numbers, your knowledge is of a meager and 
unsatisfactory kind’ 
                                     Lord Kelvin, 1891 
  
   
  
 
Abstract 
Children with problematic severe asthma (PA) have persistent symptoms and/or severe 
exacerbations despite treatment with high doses of currently available asthma medications. The 
term PA includes children who are difficult to treat due to unidentified exacerbating factors 
(e.g. allergens or environmental hazards, comorbidities, psychological and social issues, and/or 
poor adherence) and those lacking identifiable aggravating factors but, nonetheless, do not 
respond well to asthma therapy. Children with PA are a heterogeneous group of patients with 
varying clinical presentations, pulmonary function and patterns of inflammation. 
This thesis is based on the results of a Swedish nationwide cross-sectional study 
in which school aged children with PA (n=57) were compared to age matched peers with 
persistent, but controlled asthma (CA), (n=39). The major objectives were to identify 
distinguishing features of children suffering from PA, to differentiate between children who 
were difficult to treat and those who were severely resistant to therapy and to investigate novel 
and potentially clinical relevant biomarkers of PA. PA was defined by insufficient asthma 
control despite high doses of inhaled corticosteroids. 
The protocol included a detailed characterization of: history and clinical 
presentation; pulmonary function; bronchial hyperresponsiveness; inflammatory biomarkers in 
blood (including white blood cells, interleukin-5 and chitinases (chitotriosidase and the 
chitinase-like protein YKL-40)), urine (EPX) and exhaled air (FeNO); allergy (IgE antibodies, 
component resolved allergy diagnostics, basophil allergen threshold sensitivity (CD-sens)); 
morphology (computerized tomography of sinuses and lungs (in the PA group only)). 
The major distinguishing features of children with PA involve familial 
background (heredity, socioeconomic status), clinical presentation (comorbidities and triggering 
factors) and pathophysiological differences including degree of airway obstruction, bronchial 
hyperresponsiveness and inflammatory profile (IL-5, number of eosinophilic and neutrophilic 
cells in blood). Sixty percent of children with PA had therapy-resistant asthma, with the 
remainder being difficult to treat due to identified aggravating factors.  
Individual IgE-responses were similar between children with PA and CA. 
Children with PA were more often multi-sensitized to > 3 single lipocalin (nMus m 1, rEqu c 1, 
Fel d 4, rCan f 1, 2), kallikrein (rCan f 5) and secretoglobin (rFel d 1) allergens compared to 
children with CA. Cat-allergic children with PA had higher allergen sensitivity, as measured by 
CD-sens, compared to cat-allergic peers with CA. Furthermore, CD-sens correlated with 
clinical markers of asthmatic disease, including asthma control and biomarkers of eosinophilic 
inflammation.  
YKL-40 levels and chitotriosidase activity were increased in the serum of 
children with PA, and YKL-40 specifically correlated with airway remodelling (as assessed by 
computerized tomography) and blood neutrophils in children severely resistant to asthma 
therapy.  
By employing a comprehensive and standardized clinical assessment we have 
discerned specific features of children with PA and identified children who are severely 
resistant to therapy. We have applied two novel methods of allergy diagnostics (Component 
resolved diagnostics and CD-sens) and found that these two methods provide relevant 
information when investigating children with PA. Finally, our findings confirm that YKL-40 is 
a potential biomarker of asthma severity and airway remodeling. A translational research 
approach is necessary when investigating associations between disease mechanisms and clinical 
presentation in complex diseases. 
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1 INTRODUCTION 
Asthma is defined by airway inflammation, completely or partly reversible airway 
obstruction and bronchial hyperresponsiveness which collectively induce cough, 
dyspnoea and wheeze in the affected patient, Figure 1. Symptoms of asthma may be 
caused by allergen exposure, viral infections, physical exercise and airway irritants 
such as tobacco smoke. 
 
 
 
 
The prevalence of asthma increased during the second half of the 20
th
 
century, (4-5). However the worldwide prevalence of childhood asthma seems to have 
reached a plateau during the two last decades (6) and in Swedish children (age 7-8), the 
prevalence of current wheeze is 13.0 % whereas the prevalence of physician diagnosed 
asthma is 5.7% at age 7-8 and 7.7% at age 11-12 (7). Deaths from asthma were 
increasing until the end of the 20
th
 century (8) but this trend has also been broken (9). 
Nonetheless, 37 Swedish children and young adults died because of asthma from 1994 
to 2008 (10), demonstrating that there are still children with uncontrolled disease who 
need special attention. 
In an ideal situation, asthma should be suspected in a child with 
symptoms of airflow obstruction, and a spirometry should be performed to verify the 
diagnosis (11). Alternative diagnoses should be excluded, and whenever spirometry 
fails to confirm obstruction, a bronchial provocation test should be performed to 
demonstrate bronchial hyperresponsiveness. However, in clinical pediatric practice, the 
diagnosis of asthma is often based on clinical history and the response of the child to a 
trial of asthma medications, since both spirometry and assessment of bronchial 
hyperresponsiveness are troublesome, particularly in preschool children.  
The goal of pediatric asthma treatment is to enable the children to control 
their symptoms, to be able to lead a normal active life, to have a normal lung function 
as well as prevent asthma exacerbations (12). A stepwise therapeutic approach is 
Figure 1. Relationships between symptoms, airway inflammation, and 
abnormalities of airway function, with permission from (2). 
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applied to adjust medications according to symptoms and several guidelines have been 
published to support the physician in these treatment decisions (e.g. the Global 
initiative for asthma, National Asthma Education and Prevention Program). 
Caring for children with asthma does not only include the prescription of 
asthma medications. The children and their families need to be convinced and educated 
so that the child actually takes the medication as prescribed, in a proper manner. 
Furthermore, health care providers must teach the families how to avoid or handle 
triggering factors, such as allergens, to recognize signs of asthma worsening and seek 
medical advice when needed. 
The majority of children with asthma have mild or moderate disease and 
can obtain adequate control of symptoms through the avoidance of triggering factors 
and / or with the help of medications such as short acting inhaled β2-receptor agonists 
(SABA), inhaled corticosteroids (ICS) and when required, the addition of long acting 
β2-receptor agonists (LABA) and leukotriene receptor antagonists (LTRA) (13). 
However, approximately 5% of all children with asthma have chronic symptoms and/or 
recurrent exacerbations despite maximum treatment with conventional medications 
(14). These children are referred to as severe asthmatics, and due to the lack of specific 
biomarkers for this disease category, severe asthma is currently being defined on the 
basis of the intensity of the treatment required to improve asthma control, and the level 
of control achieved (15). 
Children with such severe symptoms are heterogeneous with respect to 
triggering factors, pulmonary function (16) pattern of inflammation (17) and clinical 
symptoms (18-20). These children have a reduced quality of life (21), account for a 
large proportion of the health care costs related to asthma (22-23) and represent a 
continuous clinical challenge for the paediatrician (24). Previous investigations of 
patients with severe asthma, both adults (25-26) and children (20, 27), have involved 
varying definitions, geographical and ethnic backgrounds, inclusion criteria and study 
designs and the results are not necessarily applicable to Swedish children with severe 
asthma. 
A GA2LEN task force, the Problematic Severe Asthma initiative has 
proposed the term Problematic Severe Asthma (PA) to define all children who suffer 
from chronic symptoms and/or severe exacerbations despite the prescription of several 
drugs (18, 28) and this concept has been incorporated in the recent WHO definition of 
severe asthma (29). The advantage of the newly introduced term is that it encompasses 
two groups of children; 1) children who after a thorough work up can be classified as 
difficult to treat because of identified exacerbating factors, and 2) children who 
following a thorough work up do not have any identifiable aggravating factors but are 
severely resistant to therapy, Figure 2. 
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Figure 2. Clinical classification of children presenting with Problematic severe 
asthma, from (18). 
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2 BACKGROUND 
 
2.1 CLINICAL PRESENTATION  
School-age children with PA either present with chronic symptoms on most days, or 
with acute exacerbations with or without symptoms between exacerbations. They might 
also present with persistent airflow obstruction which is unresponsive to a trial with 
steroids (18). Allergic comorbidity, including, rhinitis eczema and food allergies is 
common in this age group and severe anaphylactic asthma exacerbations after allergen 
exposure pose a particular risk to these children. Asthma symptoms are most 
commonly caused by exercise and infections. In these ages, adherence to prescribed 
treatment is still dependent upon carers but pulmonary function measurements and 
indirect assessments of inflammation can be reliably performed. 
 
2.2 LONGITUDINAL STUDIES  
There are only a few follow-up studies on children with PA; Fitzpatrick et al. found no 
changes in clinical presentation and severity in a 3 year follow-up of school age 
children (30) and Gupta et al. found that 34 of 44 school age children with PA still were 
treated with ICS and LABA, although one in six were well controlled on therapy in a 5 
year follow up (31).  
In the Melbourne study, 83 subjects with severe childhood asthma were followed 
from 10 years of age. At age 42, 90 % still had symptomatic asthma, and 45% had 
persistent asthma (32). The mechanism of the transition from predominantly atopic 
males in severe childhood asthma to non-atopic females (25) in severe adult asthma is 
largely unknown. 
 
2.3 PULMONARY FUNCTION 
Reversible obstruction of the airways is one of the pathophysiological hallmarks of 
asthma and is assessed objectively with spirometry. Forced expiratory volume in one 
second (FEV1), has been considered the most helpful marker. FEV1 has been shown to 
correlate with asthma symptoms, (33-34), exacerbations (35) and asthma control (36). 
However, some studies have failed to demonstrate significant correlation between 
FEV1, daytime symptoms, quality of life and the need for rescue medication (37-39) 
and furthermore, pulmonary function might be normal in many children with asthma 
(11). 
 A decreased FEV1 has also been used to define severe asthma in children in 
clinical studies (27, 40) but this criterion is an adaption from adult medicine and is not 
validated in a childhood population. Specific studies on severe asthma in childhood 
have yielded inconsistent results regarding pulmonary function, some studies found that 
FEV1 was on average lower in children presenting with PA although the magnitude of 
airflow limitation was significantly less in children, compared to adults with severe 
asthma (27, 41). Other studies found no difference in FEV1 on average (14, 16, 42-43), 
but there were large individual variations (44). Taken together, the results from these 
studies implicate that the usefulness of FEV1 as indicator of severity in childhood 
asthma remains unclear.  
 
2.4 BRONCHIAL HYPERRESPONSIVENESS 
Bronchial hyperresponsiveness (BHR) is another characteristic feature of 
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asthma (45) and means that the lower airways constrict in response to a stimulus (i.e. 
allergen, tobacco smoke) which is harmless to a healthy person. Methacholine 
provocation is classified as a direct airway challenge since methacholine induce airflow 
limitation via a direct stimulatory effect on cholinergic receptors on the smooth muscle. 
In indirect challenges (such as inhaled Mannitol), airflow limitation is induced as a 
consequence of changed airway osmolarity, which leads to the release of mediators or 
cytokines from inflammatory cells, mast cells in particular, thus inducing a secondary 
bronchoconstriction.  
Methacholine provocation is highly sensitive to detect BHR but it is not 
specific to asthma (46) as a positive test can also be found in other diseases such as 
rhinitis and chronic obstructive pulmonary disease. However, a negative test has a 
greater value in ruling out asthma, at least in the treatment naïve patient (11). One 
disadvantage of methacholine provocation is that it requires a baseline FEV1>70% to 
be performed safely. 
BHR to methacholine has been shown to correlate with asthma severity in 
a large cohort of children with different manifestations of persistent asthma (47) and 
this finding has been verified in specific studies on children with PA (14, 27). 
Furthermore, BHR to methacholine is reduced by anti-inflammatory treatment and has 
been shown to correlate with the number of inflammatory cells in biopsies (48) and 
markers of airway inflammation, including the fraction of nitric oxide in exhaled air 
(FeNO) in severe asthmatics (49-50).  
 
2.5 INFLAMMATION  
Airway inflammation is a pathophysiological characteristic of asthma mediated by the 
infiltration of inflammatory cells including mast cells, eosinophilic and neutrophilic 
granulocytes, plasma cells and structural cells in the airway wall. This cell infiltration 
subsequently leads to damage of the airway epithelium, neuroadrenergic imbalance, 
mucus secretion, unpredictable smooth muscle contractions, bronchial 
hyperresponsiveness and in the case of chronic inflammation, persistent morphological 
changes to the airways, i.e. airway remodelling (51).  
The level of symptoms and markers of inflammation do not always 
correlate, some children might have persistent symptoms, without any histologically 
detectable inflammatory cells (52), whereas other children might have no symptoms 
between exacerbations but still have increased markers of airway inflammation (53). 
Nevertheless, the number of inflammatory cells present in the airway epithelium are 
higher in symptomatic compared to non-symptomatic children (40). 
The aetiology of airway inflammation in asthmatic children varies 
according to age. Whereas viral infections, including rhinovirus and respiratory 
syncytial virus are linked to obstructive bronchitis in infancy and early childhood, 
sensitization and exposure to allergens is a major cause of airway inflammation in older 
children. Interestingly, recent evidence points to a synergistic effect between viral 
infections and aeroallergen exposure and the subsequent sensitization in genetically 
predisposed children (54). Furthermore, viral infections have been shown to be the 
most important cause of asthma exacerbations in all age-groups (55). Rhinovirus and 
respiratory syncytial virus are shown to damage the respiratory epithelium, making it 
less resistant to inhaled allergens subsequently leading to enhanced Th2 responses in 
liable children and the development of allergic inflammation. 
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The process of allergic sensitization is described in Figure 3 and the early 
phase allergic reaction is described in Figure 4. In addition, it should be noted that mast 
cells can be activated directly by pathogens such as bacteria and physical stimuli 
including osmolarity changes during exercise. 
 
 
 
Figure 3. Sensitization to allergens in the airway of an atopic individual i.e. a 
person with a tendency to produce IgE antibodies in response to low doses of 
allergens, with permission from (3). The first time an atopic individual is exposed 
to an allergen, dendritic cells located in the airway mucosa recognize the allergen 
as body-foreign material, ingest the antigen and move towards the nearest lymph 
node. Fragments of the ingested antigen are presented on the major 
histocompatibility complex (MHC) which together with other co-stimulatory 
molecules bind to the respective receptor on a T-helper cell. The T-cell response 
varies depending on the individual’s genetic constitution and the nature of the 
presented antigen. In the atopic individual, naive T-helper (Th) cells will 
differentiate into Th2 cells producing IL-4, IL-5, IL-9, IL-13 GM-CSF and 
eotaxin. These cytokines stimulate B-cells to produce specific IgE antibodies, to 
recruit eosinophilic cells from the bone marrow and homing of mast cells. Mast 
cells are differentiated from CD34 precursor cells in the bone marrow, they are 
normally not identified in blood, but migrate, guided by chemotaxins, to tissues 
throughout the body, although the highest numbers are found in the skin and in 
the airway and gastrointestinal mucosa. The IgE produced by B-lymphocytes will 
circulate in serum with a half life of 2-4 days and the FC region of the IgE 
antibodies will bind to high affinity receptors (FcεR1) on tissue mast cells with a 
half life of 2-4 weeks and the person is now sensitized. 
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The late phase allergic reaction includes the recruitment and migration of 
T-cells and other inflammatory cells including eosinophils and neutrophils to the site of 
allergen exposure within 4-6 hours. The granulocytes are recruited and developed from 
a pluripotent stem cell in the bone marrow via the circulation to the airways. Interleukin 
3 (IL-3), IL-5 and granulocyte macrophage-colony stimulating factor (GM-CSF) 
secreted by Th2 cells and mast cells are the most important interleukins for eosinophilic 
development and recruitment, although only IL-5 is specifically targeted towards the 
eosinophils. Once matured and recruited to the circulation, eosinophils adhere to the 
endothelial wall, connecting with adhesion molecules expressed on the eosinophil 
(Very late antigen-4) and endothelial cells (Vascular cell adhesion molecule-1).  
After transmigration through the endothelial wall, the eosinophils are 
guided to the site of inflammation by chemokines, and release several stored toxic 
mediators, including free acid radicals, eosinophil cationic protein (ECP), eosinophil 
peroxidase, eosinophil protein x (EPX) and leukotrienes. 
The physiological effects of the mediators excreted from eosinophils in 
the bronchial wall include smooth muscle contraction, increased vascular permeability, 
Figure 4. Early phase of allergen-induced airway inflammation, with permission 
from (3).  When a sensitized individual is exposed to an allergen, the allergen will 
cross bind the variable part of two IgE antibodies on the mast cell, which results 
in mast cell degranulation and release of tryptase, histamine (within 10 minutes), 
leukotrienes, prostaglandins (within 30 minutes) which collectively lead to 
vasodilatation, bronchospasm and increased vascular permeability. These early 
events are known as the early phase allergic reaction.  
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increased BHR and production of toxic intermediate products and lipid peroxidation 
ultimately leading to injury and shedding of the surface epithelium. Collectively these 
mechanisms contribute to the establishment of chronic airway inflammation. 
 Markers of lipid peroxidation, nitrite and oxidized glutathione (the most 
important extracellular antioxidant) are increased in children with severe asthma and 
persistent airflow limitation compared to mild-to-moderate asthmatic children (56-57). 
In addition, oxygen free radicals in severe asthmatic children are associated with 
impaired alveolar macrophage phagocytic function (58), which could explain the 
increased susceptibility to infections with capsular polysaccharide bacteria in severe 
asthmatic children (59). 
Neutrophils are attracted by cytokines such as GM-CSF and IFNγ. 
Neutrophilic pathogenic excretions include elastase which causes hypersecretion and 
hyperreactivity; matrix metalloproteinase 9 (MMP-9) which breaks down collagen and 
causes hypersecretion and free oxygen radicals which also induce bronchial 
hyperreactivity (60). 
The relative contribution of each of these cell types to asthma severity is 
not clear and a sustained expression of pro-inflammatory cytokines and chemokines 
that are not Th2 dominant has been found in BAL fluid from severe asthmatic children 
(61). Nevertheless, airway eosinophilia has been shown to persist in children with PA, 
despite treatment with corticosteroids (62) although in a recent published study on 
children with therapy resistant asthma there was a huge variability in eosinophil counts 
in BAL fluid and biopsy material (63). In addition, correlations between asthma 
severity, eosinophil activation (64) and bronchial hyperresponsiveness (65) have been 
demonstrated. The number of neutrophils in bronchoalveolar lavage fluid has been 
shown to correlate with asthma severity in children (59), but in a recent study of 
children with therapy resistant asthma no signs of neutrophilic airway inflammation 
were found in BAL fluid and biopsy material (63). 
 
2.5.1 Airway remodelling and computerized tomography 
Airway remodelling refers to structural changes in the bronchial wall (66) causing 
reduced lung function (67) in asthmatic patients. These structural changes are 
confirmed by histological analysis and are characterized by sustained tissue 
eosinophilia, epithelial damage, thickening of reticular basement membrane (RBM), 
subepithelial fibrosis as well as mucus gland and airway smooth muscle hypertrophy 
and hyperplasia (68-69). Increased hypertrophy of the smooth muscle has been 
associated to reduced lung function in severe asthma (70). Remodelling is found in the 
majority of school age children with PA (43) and the progressive loss of lung function 
found in these patients (30) is probably caused by remodelling.  
Bronchial wall thickening (BWT) can be identified by high resolution 
computerized tomography (HRCT), and has been proposed to be a surrogate marker of 
airway remodelling (71). BWT can be assessed quantitatively based on the number of 
visible bronchi at different levels of the lung by HRCT, and increased bronchial wall 
thickening has been found in children with moderate to severe asthma compared to 
healthy controls (72-73). In adults, BWT correlates with asthma severity, airflow 
obstruction (74) and RBM thickening (75-76). 
In children, BWT has been shown to correlate with the thickness of the 
RBM (r=0.34) and ECP levels (r=0.45). However, these results have not been 
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confirmed in other studies (77) and no correlations have been found with lung function 
measurements or levels of IFN-γ, IL-4, IL-5 in BAL fluid (78). 
 
2.6 BIOMARKERS IN PEDIATRIC ASTHMA 
A biomarker reveals information about the investigated disease and can be used in one 
or more of the following settings; to assess risk for morbidity, identify disease or 
disease phenotypes and to monitor disease activity as well treatment effects (79). The 
ideal biomarker is attained non-invasively, is reproducible and easily measured and 
provides information about essential pathophysiological processes with high 
performance characteristics including sensitivity, specificity, negative and positive 
predictive values. 
Using biomarkers in the context of childhood airway disease is 
particularly challenging. Imaging and spirometry, although providing relevant 
information as described previously, also have significant limitations. Biological events 
that occur episodically (bronchoconstriction) might not be captured and in early or mild 
disease these methods might show normal results despite the patient having symptoms 
(79). 
Invasive methods such as those used to obtain biopsy and BAL fluid are 
possible in specialized centres, but in most circumstances they are not considered 
feasible in children. Induced sputum, a semi-invasive method, has been found to be safe 
in children but does require specially trained staff (80). In adults treatment guided by 
the presence or absence of sputum eosinophils has been shown to reduce asthma 
exacerbations (81), but this has not been proven effective in severe asthmatic children 
(82). 
 
2.6.1 Exhaled Nitric oxide 
Nitric oxide (NO) is produced by NO-synthase in airway epithelial cells and the 
resulting NO can easily diffuse into the airway lumen. The fraction of NO in exhaled 
air (FeNO) is currently being established as a non-invasive biomarker in asthma. FeNO 
has been shown to be elevated in patients with atopic asthma (83), to correlate with the 
degree of IgE sensitization (84), elevated in connection with allergen exposure (85) 
reduced by treatment with inhaled corticosteroids (86) and correlates with the number 
of eosinophils in blood (87), induced sputum (50) and biopsy specimens (62). Thus, 
FeNO seems to be a marker of the physiological consequences of atopy, i.e. the 
inflammation caused by allergen exposure.Nevertheless, the clinical situation in which 
FeNO provides the most useful information is currently debated (11), and the 
relationship between FeNO and asthma severity is unclear (49). 
Height has also been shown to be a independent variable for FeNO, probably 
because of a larger airway mucosa in taller subjects and an increase in height from 120 
to 180 cm is associated with a doubling of FeNO levels (88-89). 
 
2.6.2 Chitinases 
A group of proteins recently discovered to be potential biomarkers of asthma are the 
chitinases. Chitin is a tough structural polysaccharide, the second most abundant 
biopolymer in nature after cellulose, used by a variety of organisms including insects, 
crustaceans, parasites, fungi and bacteria to protect against harsh environmental 
conditions (90). Although chitin is not present in the human body, we express enzymes 
capable of its degradation. Two members of this family, the enzymatically active 
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chitotriosidase and the enzymatically inactive chitinase-like protein YKL-40, are 
increased in the serum of asthmatic patients (91-92). Furthermore, levels of YKL-40 
have been shown to correlate with markers asthma severity (92) and it has been 
suggested that the chitinases may be involved in the development of fibrosis and 
remodelling of the airway (93). 
A promoter single nucleotide polymorphism (SNP) in the gene encoding 
YKL-40, CHI3L1 rs4950928 (-131C→G) has also been associated with increased 
circulating levels in serum and features of asthma (94). Chitotriosidase activity is also 
subject to genetic regulation, with individuals homozygous for a 24bp duplication in 
exon 10 of CHIT1, the gene coding for chitotriosidase, displaying complete enzyme 
inactivity (95). 
 
2.7 ALLERGY AND ALLERGENS  
IgE mediated allergy leading to allergic inflammation, as described above, is common 
among children with persistent asthma. The presence of allergy predict both long-
lasting (32) and troublesome asthma (96-97) in adult life and ongoing allergen exposure 
affects the frequency of asthma symptoms (98). Finally, comorbidities between 
different allergic diseases, including food allergies, atopic eczema and rhinitis are 
common, and the latter has been shown to be a risk factor for developing asthma (99) 
and contribute to reduced symptom control in asthmatic children (100). 
 
2.7.1 Allergens 
Antigens which cause an IgE mediated reaction are defined as allergens. The most 
common sources of inhaled allergens that affect Swedish children are tree and grass 
pollens and furred animal dander (cat, dog) whereas peanut, egg and milk are the most 
important food allergen sources. Every allergen source consists of several allergens, 
each of which might have the capacity to bind to IgE (101). The allergens are named 
after the three first letters in the Latin family name followed by the fist letter of the 
species name and a number, e.g. Betula verucosa 1 (Bet v 1) refers to birch allergen 1.  
In addition, every allergen has several epitopes, and similar epitopes might 
occur in allergens from different allergen sources, which is the biological explanation 
underlying cross sensitization (102).  
Some allergens are unique markers of a specific allergen source whereas other 
allergens with similar structure and functions are found in different species, for 
example lipocalins is a group of proteins arising from cat, dog, horse and mice and 
cross-reactivity within these groups of proteins is common (103-104).  
  
2.7.2 Diagnosing allergy 
A thorough clinical history and assessment of allergic sensitization are the cornerstones 
of an allergy diagnosis. Sensitization is usually determined by using allergen extracts to 
identify the disease eliciting allergen source, either by in vivo (skin prick testing) or in 
vitro testing, i.e. measurement of specific IgE in serum. However, one disadvantage 
with these extract based methods is that they only provide information about the 
possible sensitizing allergen source, but no information about sensitization towards 
specific allergens is provided. Thus, it is not possible to differentiate between the 
primary source of sensitization and cross-reactivity between allergens from different 
allergen sources (105), and it is not possible to determine whether the patient is 
sensitized to an allergen causing severe reactions or allergens causing mild reactions.  
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2.7.3 IgE component resolved diagnostics 
Component-resolved allergy diagnostics is a new concept for measuring specific IgE 
towards single allergens in vitro e.g. by using an allergen microarray chip (106).The 
only commercially available component-based microarray platform for allergy is the 
immunosolid-phase allergen chip (ISAC, Phadia, Sweden). Although the ISAC chip 
lacks some minor allergens, the most common species-specific and cross-reactive 
allergens are represented. Some allergens are specific markers of an allergen source 
(107), and by identifying these allergens it is possible to determine which are the 
sensitizing allergen sources and which are the cross-reactive allergen sources (108). 
Furthermore, it is sometimes possible to predict whether the patient is at risk for a 
severe or mild reaction, based upon which allergen the patient is sensitized to. For 
instance, children allergic to peanut and sensitized to the allergens Ara h 1, Ara h 2 and 
Ara h 3 are at risk for significantly more severe symptoms upon peanut exposure 
compared to children sensitized to Ara h 8 (109), which is a homologue of the major 
Birch allergen, Bet v 1. 
 
2.7.4 Basophils 
Basophils share important features with mast cells as they are both developed from 
CD34 positive stem cells in the bone marrow, express FcεRI on their surface and store 
histamine containing granulae which are released upon crossbinding of allergens to IgE 
bound to FcεRI. Circulating basophils are more accessible than tissue resident mast 
cells, and this is the reason for using basophils as a marker of mast cell activity (110).  
 
2.7.5 Basophil allergen threshold sensitivity (CD-sens) 
Assessment of allergen specific IgE antibodies does not necessarily predict the degree 
of sensitivity to a particular allergen, i.e. the effector cell response and the subsequent 
clinical symptoms upon allergenic stimulation. For this purpose allergen provocation 
challenge tests are needed, but as they are potentially harmful, especially in severe 
asthmatic children, few studies on in vivo allergen challenge tests have been feasible 
and published in children with severe asthma.  
An attractive in vitro alternative to the clinical allergen provocation test 
has been established (111). Basophil allergen threshold sensitivity (CD-sens) is a 
method for quantification of allergen sensitivity which correlates well with in vivo 
allergen provocation (112-113). Basophils express CD203c on their surface, which 
makes it possible to reliably identify these cells in a blood sample (114). Upon 
stimulation, basophils release their histamine containing granulae and CD63, which is 
situated in the vesicles of the granulae, subsequently becomes exposed on the cell 
surface (115). CD-sens is based on the flow cytometric detection of CD63 on basophils 
following an in vitro allergen titration. The allergen concentration causing 50% of 
maximum basophil activation (measured by CD63 up-regulation) is used to calculate 
CD-sens, Figure 5 and Figure 6. Therefore CD-sens is a measurement of the 
sensitivity of basophils to a particular allergen. 
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3 RATIONALE AND AIMS 
 
Clinical characterization (I) 
The clinical presentation of children with Problematic severe asthma (PA) in Sweden 
has not previously been described and the applicability of the recently introduced 
definition of PA, with the subgroups of difficult to treat asthma and severe therapy 
resistant asthma, has never been addressed. In addition, identification of novel 
biomarkers of asthma severity is needed. 
The aims were to provide a detailed characterization of Swedish children 
suffering from PA and through a standardized and non-invasive protocol, investigate 
whether it would be possible to identify children who are severely resistant to therapy. 
A further aim was to compare children with PA to age-matched peers with controlled 
persistent asthma (CA) and to identify distinguishing features between these two 
patients groups. Finally, we also aimed to provide baseline data of these two patient-
groups and generate hypothesis for exploring biomarkers of asthma severity and follow 
up studies. 
 
Component resolved allergy diagnostics (II) 
Assessment of allergic sensitization by the established extract based methods have 
diagnostic limitations, both with respect to concordance (116), cross reactivity and 
prediction of severe allergic reactions. Component resolved diagnostics is a new 
concept for measuring allergens in vitro and the main advantage of this method is that it 
enables identification of cross-reactive or species-specific allergens, and allergens 
associated with mild or severe reactions. The added value of performing this analysis in 
children with persistent asthma has not been investigated previously. The aim was to 
assess the usefulness of component resolved allergen diagnostics in the assessment of 
children with different manifestations of persistent asthma.  
 
Basophil allergen threshold sensitiviy (CD-sens) (III) 
A possible mechanism for the development of PA in allergic children is increased 
sensitivity to allergens, which would imply that the allergic inflammation is triggered 
by lower allergen concentrations in children with PA compared to children with CA. 
This hypothesis can be tested using CD-sens.  
The aim of this study was to examine whether CD-sens was increased in 
children with PA compared to CA and investigate correlations between CD-sens and 
other biomarkers of asthma. 
 
Biomarkers of inflammation (IV) 
Specific biomarkers of PA are needed to improve the characterization of this 
heterogeneous patient group, to increase the understanding of the underlying 
pathophysiology and to select patients for the most appropriate “beyond-the-
guidelines” treatment. Chitotriosidase and the chitinase-like protein YKL-40 have been 
shown to be increased in the serum of asthmatic patients, to be involved in the 
development of remodelling of the airway and levels of YKL-40 have also been shown 
to correlate with markers of disease severity. Little is known about the expression and 
regulation of YKL-40 and chitotriosidase in relation to asthma in children. 
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The aim of this study was to examine serum YKL-40 levels and 
chitotriosidase activity in children with different manifestations of persistent asthma 
and further, to investigate potential correlations between YKL-40, bronchial wall 
thickening assessed by HRCT, pulmonary function measurements, and other 
biomarkers of inflammation. 
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4 METHODS 
The present dissertation is based upon the Swedish severe asthma study. The study was 
approved by the regional board of ethics at Karolinska Institutet (Dnr 2006/1324-31/1). 
 
4.1 STUDY DESIGN AND INCLUSION CRITERIA (I-IV) 
The Swedish severe asthma study was designed as a nationwide observational study in 
which school aged children (6-18 years) with problematic severe asthma (PA) were 
compared to age-matched peers with controlled persistent asthma (CA). These two 
conditions were defined in accordance with the GINA guidelines (12), which take into 
account the severity of the underlying disease, as indicated by the need for treatment 
and degree of symptom control achieved. The inclusion criteria are presented in Table 
1. 
 
4.2 RECRUITMENT AND SUBJECTS (I-IV) 
Allergists working at 27 pediatric clinics throughout Sweden were invited to refer 
children with PA and age-matched peers (±12 months) with CA for this investigation. 
Sixteen of these clinics (6 at university hospitals and 10 at general hospitals) from all 
regions of the country responded. In addition, journal charts from 4 clinics were 
systematically reviewed to identify children with CA. The children identified and 
referred in this manner were then invited by mail, telephone or verbally in connection 
with a visit to their doctors to participate. Following reassessment of their medical 
histories, medication and adherence to prescribed treatment, final selection of the 
participants was performed according to the criteria documented in Table 1. The 
children who admitted that they could miss more than 3 doses of prescribed medication 
per week were considered ineligible for inclusion, and likewise, children with vocal 
cord dysfunction, cystic fibrosis, immunodeficiencies, serious neurological disease or 
who had undergone major lung surgery or been born before 36 weeks of gestational age 
were excluded.  
In paper I, 54 children with PA and 39 children with CA from 15 clinics 
were investigated. The analysis in Paper II and IV comprised 57 children (56 in Paper 
II) with PA and 39 children with CA, recruited from 16 clinics. Paper III included 11 
cat allergic children with PA and 11 cat allergic children with CA from three clinics. In 
addition, in paper IV, 27 school-aged healthy controls were included for comparison.  
 
4.3 PROCEDURES 
Information was collected at each child´s regular clinic or at the research clinic at 
Astrid Lindgren Children´s Hospital in connection with two or three visits. A team 
consisting of myself and a research nurse (Björn Nordlund) visited the participating 
clinics and conducted the interviews and the majority of the procedures on site, 
utilizing brought equipment, to ensure standardized collection of biological samples 
and data. The children were required to have been free from airway infection or 
exacerbation of their asthma during the 2-week period prior to examination.  
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Problematic severe asthma (PA) Controlled persistent asthma (CA) 
Major criteria (all required) Major criteria (all required) 
 A diagnosis of asthma by a pediatric 
allergist 
 A diagnosis of asthma by a pediatric 
allergist 
 Daily high-dose administration of 
ICS (≥800 μg budesonide or ≥400 μg 
fluticasone/momethasone per day) in 
combination with LABA and/or 
LTRA* 
 Daily low- to medium-dose 
administration of ICS ( ≥100 - ≤400 
μg budesonide or ≥50 - ≤200 μg 
fluticasone per day). Use of either 
LABA or LTRA was acceptable. 
Minor criteria observed within the 
preceding 12-month period (minimum of at 
least one required) 
Minor criteria observed within the 
preceding 12 month period (all required) 
 at least one emergency hospitalisation   no hospitalisation 
 at least two emergency out-patient 
visits  
 no emergency out-patient visits 
 at least one oral treatment with 
corticosteroid  
 no oral corticosteroid treatment 
 at least twelve exacerbations of 
asthmatic symptoms per year or 
symptoms present continuously for at 
least 3 months  
 less than five exacerbations of 
symptoms** 
 symptoms that limited daily activities 
(including sport or leisure activities) 
more than twice a week for at least 
three 3 consecutive months 
 occasional symptoms related to 
strenuous exercise only, otherwise no 
symptoms 
 nocturnal symptoms more than twice 
a week for at least three consecutive 
months 
 no nocturnal symptoms 
Table 1. Inclusion criteria for the children recruited to the study. ICS Inhaled 
corticosteroid; LABA long-acting β-2 agonist; LTRA leukotriene receptor 
antagonist,  
*High-dose administration of ICS for at least 6 months during the preceding year; 
previous use of LABA or LTRA only was considered acceptable if this treatment 
was discontinued due to inefficacy or the occurrence of unacceptable side-effects. 
* *An increase in the ICS dosage for a maximum of 2 weeks in connection with 
asthma exacerbations was considered acceptable. 
 
 
4.3.1 Interviews (I-IV) 
The children and their parents were interviewed using a standardized questionnaire, 
which was a modified version of the one employed in the Environmental and 
Childhood Asthma Study (117). The questionnaire includes enquiries regarding 
demographic data; family history; indoor environment; exposure to tobacco smoke, 
pets and outdoor pollution; level of physical activity; symptoms or previous diagnosis 
of rhinoconjunctivitis (sneezing, congestion, secretions, itchiness, seasonal variation) 
and/or gastroesophagal reflux disease (GERD) (heartburn, regurgitation, upper 
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abdominal pain); occurrence of atopic disease; anaphylactic reactions; use of asthma 
medication; adherence to medication (evaluated with a three-point scale ranging from 
missing on the average < 1 to missing >3 doses of prescribed medications per week); 
asthmatic symptoms and their exacerbations (118); triggering factors ; and utilisation of 
health care services. The percentiles of age- and sex-adjusted body mass indices (BMI) 
were calculated utilizing published algorithms(119). The research nurse observed the 
ability of each child to use the inhaler properly.   
 
4.3.2 Asthma control test (II, III, IV) 
Asthma control was estimated according to the Asthma control test (120). A total of 25 
points can be achieved with optimal asthma control, and a score of 19 or less suggests 
poorly controlled asthma.  
 
4.3.3 Spirometry and methacholine provocation (I-IV) 
Treatment with SABA and/or LABA and/or LTRA was withheld for 8, 24 and 72 
hours, respectively, prior to measurement of baseline pulmonary function and 
provocation with methacholine.  
Spirometry was performed using a Vitalograph
®
 2120 (Vitalograph
®
, 
Ennis, Ireland), in accordance with published recommendations (121) and FEV1, FVC, 
FEF50 were reported using the reference values reported by Polgar (122). 
Static lung volumes were determined at each local hospital and presented 
as TLC, RV and FRC, expressed as percentages of the locally applied reference values. 
Bronchial hyperresponsiveness (BHR) to a challenge with methacholine 
was assessed utilizing a Spira nebuliser (Spira Respiratory Care Centre, Hämeenlinna, 
Finland) (123). The dose of methacholine causing a 20% reduction in FEV1 (PD20) 
(124) and the slope of the dose-response curve (DRSmethacholine) were calculated (125). 
Nebulised salbutamol (0.2mg/kg, maximally 5 mg) was administered following 
methacholine provocation and FEV1 recorded 15 minutes later. Children with a 
baseline FEV1<70% were not exposed to the methacholine challenge, however, these 
children were also given salbutamol followed by spirometry. 
 
4.3.4 Analyses in blood and urine (I-IV)  
Following application of local anaesthesia (EMLA cream, Astra Zeneca, Sweden), 
samples of venous blood were obtained and the white blood cells and C-reactive 
protein (CRP) examined. The serum concentration of Immunoglobin E (Total IgE, 
kU/L) and the levels of IgE antibodies directed specifically against the Phadiatop
®
 
mixture of common inhaled allergens, (birch, timothy, mugwort, cat, dog, horse and 
moulds (Cladosporium herbarum)); against house dust mite (Dermatophagoides 
pteronyssinus)); and against food allergens (fx5
®
=cow’s milk, egg white, soy bean, 
peanut, cod fish and wheat) (ImmunoCAP System™, Phadia AB, Uppsala, Sweden) 
were determined. Sera which demonstrated a positive reaction to Phadiatop
®
 or fx5
®
 
(defined as a level of IgE antibodies ≥ 0.35 kUA/l) were analysed further for IgE 
antibodies towards the individual allergens present in these mixtures. IgE antibodies to 
rFel d 1 were analysed by ELISA (103). Atopy was defined as level of antibodies 
towards either Phadiatop
®
 and/or fx 5
® ≥0.7 kUA/l (Paper I). Interleukin 5 was analysed 
by ELISA as part of a Multiplex cytokine assay. Eosinophilic protein X (EPX) in 
morning urine was analyzed with the EDN ELISA kit (Medical & Biological 
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Laboratories Co. Naka-Ku Nagoya, Japan), for which the lowest level of detection is 
0.62 ng/ml, and expressed as nanogram EPX per millimol urine creatinine.  
 
4.3.5 Component resolved diagnostics (II) 
All serum samples were analysed using an experimental research ISAC prototype 
(Phadia AB, Sweden) containing 111 allergen components (all components of the 
ImmunoCAP ISAC 112 chip version except Ara h 6). The chip contained allergens 
derived from 51 sources, and required 30 µl of serum per test. Details of the tested 
components are listed in Figure 9. Positive sensitization was defined by a level of ≥ 
0.30 ISAC independent units (ISU). 
 
4.3.6 CD-sens (III) 
CD-sens analyses were performed at one laboratory, as described previously (111), 18-
24h after blood sampling. The basophils were exposed to decreasing concentrations of 
cat allergen extract (Aquagen) (ALK Laboratories, Copenhagen, Denmark) followed 
by staining with CD203c (Immunotech, Marseille, France) (basophil identification) and 
CD63 (Immunotech) (basophil activation), Figure 5.  
 
 
Figure 5. Example of test report from CD-sens analysis, demonstrating the 
increased expression of CD63 with increasing allergen concentrations, with 
permission from Anna Nopp.  
CD-sens was defined as the inverted lowest allergen concentration causing 50% of 
maximum CD63 up-regulation. This value was multiplied by 100 and used to describe 
a patient’s allergen-specific sensitivity. A high CD-sens indicates high basophil 
allergen sensitivity. Basophil reactivity was expressed as the maximum upregulation of 
CD63 shown as percentages. The number of IgE molecules and FcεRI receptors per 
basophil was calculated using a FITC-conjugated antibody to IgE and FcεRI and 
compared to a standard calibration curve (111). 
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4.3.7 Exhaled Nitric oxide (I-IV) 
Employing a NIOX
TM 
(Aerocrine AB, Solna, Sweden), FeNO was measured prior to 
spirometry, at an exhalation flow rate of 50 ml/s, in accordance with international 
guidelines (126) and presented as parts per billion (p.p.b). In the extended FeNO 
analysis, the FeNO -values obtained were adjusted for height; the difference between 
measured and expected height adjusted FeNO (Ln(FeNO) = 0.0112 x height (cm) + 
0.641) was given as a percentage (%FeNO) (88). 
 
4.3.8 nasal Nitric Oxide (nNO) (I) 
Using nasal air samples obtained during breath-holding following maximal inhalation 
nNo was determined with NIOX
TM
 and a nNO value greater than 105 ppb was 
considered indicative of the absence of primary ciliary dyskinesia (127). 
 
4.3.9 YKL-40 assay (IV) 
Serum YKL-40 levels were measured by according to the manufacturer’s instructions 
(Human Chitinase 3-like 1 DuoSet ELISA Development Kit, RnD Systems, UK). Two 
different dilutions were made for each sample from which an average was obtained, 
and all samples were analysed in duplicate.  
 
4.3.10 Chitotriosidase assay (IV) 
Chitotriosidase activity in the serum was determined using the fluorogenic substrate 
4MU-deoxychitobiose as described and presented as nmol/ml/hour(128). Briefly: 25 μl 
serum, diluted with BSA/PBS (bovine serum albumin/phosphate buffered saline, 1 mg/ 
ml) and 100 μl substrate mixture, 0.111 mM 4MU-deoxychitobiose and 1 mg/ml BSA 
in McIlvain buffer (100 mM citric acid, 200 mM sodium phosphate) pH 5.2, were 
incubated for 20 min at 37 °C. Reactions were stopped with 2.0 ml 0.3 M glycine 
NaOH buffer pH 10.6 and the formed 4MU was detected fluorometrically (excitation at 
445 nm; emission at 366 nm). In order to discriminate between chitotriosidase activity 
and that of acidic mammalian chitinase (AMCase) in serum samples, a neutralizing 
antibody against AMCase was used. 
 
Figure 6. Upon cross-linking of membrane-bound IgE, basophils not only 
secrete particular mediators, but will also up-regulate the expression of specific 
activation markers such as CD63 and CD203c, with permission from (1). 
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4.3.11 Genotyping for chitinases (IV) 
The CHIT1 24bp duplication (rs3831317) was genotyped using melting curve analysis 
to discriminate the different PCR products based on the presence or absence of the 
duplication. The following forward (5'-GGAGAAGCCGGCAAAGTC-3') and reverse 
primers (5'-AGCTATCTGAAGCAGAAG-3') were used. PCR reactions were 
performed with 10 µM of each primer, in a final volume of 10 µl, using SYBR Green 
PCR Master Mix (Applied Biosystem) following the manufacturer’s recommended 
protocol. Melting curve analysis was performed as a post-PCR procedure with the SDS 
v1.4 software using the ABI Prism 7500 detection system (Applied Biosystems). The -
131 C/G polymorphism in the CHI3L1 gene (rs4950928) was analyzed using TaqMan 
allelic discrimination on the ABI Prism 7500 detection system according to 
manufacturer’s protocol (C__27832042_10, Applied Biosystems). Reruns of 10% of 
the samples for both genotypes showed 100% concordance. 
 
4.3.12 CT scanning (I, IV) 
Children suffering from PA underwent HRCT of their lungs at their local hospitals, 
within 3 months after inclusion in the study, to identify possible differential diagnosis 
and assess bronchial wall thickening. A standardized protocol was used and all images 
were evaluated by the same radiologist. HRCT scans of the lungs were obtained at full 
inspiration with 1 to 1.5 mm thick sections at 10 mm intervals through the thorax and 
images were reconstructed using a high spatial resolution reconstruction algorithm. The 
images were viewed at lung window settings optimized for paediatric lungs; window 
level -500 Hounsfield units (HU) and window width 1500 HU. The number of children 
with a significant differential diagnosis detected by HRCT is indicated and the degree 
of bronchial wall thickening (BWT) is assessed as described by Marchac et al. (72) 
using a semi-quantitative score based on the number of clearly identifiable segmental 
and sub-segmental airways at three predefined levels in the right lung. Sinus CT scans 
were scored and presented according to the Lund-MacKay system (129) with a score 
>5 indicating rhinosinusitis (130). 
 
4.3.13 Definition of patient populations 
Problematic severe asthma (PA): Children with chronic symptoms and/or recurrent 
exacerbations despite treatment with high doses of inhaled corticosteroids and other 
anti-asthmatic controller medications, according to the inclusion criteria presented in 
Table 1. 
 
Difficult to treat asthma: A sub-group of children with problematic severe asthma. In 
these children a possible explanation to their poor asthma control has been identified, 
see Figure 2 
 
Therapy resistant asthma: A sub-group of children with problematic severe asthma. 
In these children no explanations for the severe symptoms have been identified, see 
Figure 2. 
 
Controlled asthma (CA): Children with persistent asthma who achieve satisfactory 
control of symptoms with a low or moderate dose of inhaled corticosteroids, according 
to the inclusion criteria presented in Table 1. 
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Exacerbation phenotype: Children with Problematic severe asthma who had received 
more than 1 course of oral corticosteroids in the preceding 12 months, without 
experiencing daytime or night-time symptoms between exacerbations. 
 
Chronic symptoms phenotype: Children with Problematic severe asthma that had 
experienced daytime and/or night-time symptoms more than twice a week for the 
preceding three months. 
 
4.4 STATISTICS 
All information obtained was recorded on a specially constructed, computerized form 
for subsequent analysis with the Statistical Package for Social Sciences Version 16.0-
20.0. The values are presented as means and standard deviations (SD) for normally 
distributed data and as medians and inter-quartile ranges (IQR) for data not 
demonstrating a normal distribution. Categorical data are presented as percentages. For 
all comparisons a two-tailed probability of ≤ 0.05 was considered statistically 
significant. Groups of variables that exhibited a normal distribution were compared 
utilizing Student’s t-test, while for skewed variables the Mann-Whitney´s test was used.  
In paper IV, normality was tested with the Kolmogorov-Smirnov test and 
groups of variables that exhibited a normal distribution were compared utilizing 
Student´s t-test in the case of equal variance, and by Welch´s t-test in the case of 
significantly unequal variance between groups as assessed by Levene´s test. 
In all papers, associations between two categorical variables were tested 
with a Chi square test or Fisher´s exact test. Correlations were assessed employing the 
Pearson or the Spearman test. 
  Binary logistic regression analyses (Paper I) were conducted to further 
analyze applicable categorical variables which demonstrated significant differences 
between PA and CA in the univariate analysis. CA or PA was used as the dichotomous 
dependent variable, CA was assigned a value of 0 and PA was assigned a value of 1, 
and odds ratios (OR) were estimated along with the 95% confidence intervals (95% 
CI). Adjustments were made for possible confounding factors; age gender and ethnicity 
(model A) and in model B, the variables that came out with a significant result in model 
A were analyzed together. The history and trigger score (the sum of scores of the 
individual variables included in model A, each of which was assigned a value of 0 = no 
or 1=yes) were calculated to integrate information provided by the different variables 
concerning each patient´s history. Regression analyses of history score and trigger 
score were performed to assess the OR associated to PA or CA with every stepwise 
increase in each of these scores.  
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5 MAIN RESULTS 
 
In total, 57 children with PA and 39 children with CA were included and investigated, 
Figure 7.  
 
 
 
 
5.1 CLINICAL CHARACTERISTICS (I) 
54 children with PA were compared to 39 age matched children with CA in this 
analysis. Children with PA and CA were similar with regards to age (13.1 (3) vs.13.8 
(2.9) years, p=0.28), gender distribution (39% vs. 41% females, p=0.84) and BMI 
percentile (63 (28) vs.55 (29), p=0.15) and the majority of children in both groups were 
Caucasians (83% vs. 92%, p=0.20) 
 
5.1.1 History 
In univariate analyses, children with PA were more likely to have parents with asthma 
(p=0.003), less income (p=0.03) and less formal education (p=0.01) compared to 
children with CA. Furthermore, children with PA were less physically active (p=0.04), 
Figure 7. Flow of patients from referral to final classification. 
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needed more health care services (p<0.001) and had a trend towards more smoking in 
their family (p=0.05). Finally, children with PA had more comorbidity with 
rhinoconjunctivitis, whereas eczema, food allergy and a history of anaphylactic 
reactions were equally as common in these two groups of patients (presented in 5.3.1.). 
Results from the binary logistic regression analysis are presented in Table 2. 
 
Parameter Model A 
(adjusted for age, 
gender and ethnicity) 
Model B 
(Multivariate 
analysis) 
 
n OR 95% CI p OR 95% CI P 
Parents without education 
beyond high school 
85 3.4 1.2-9.5 0.02 3.6 1.1-12 0.04 
At least one parent with 
asthma 
92 3.9 1.6-9.5 0.003 3.5 1.2-10 0.02 
At least one family member 
who smokes 
92 2.7 1.01-7.1 0.048 1.7 0.4-6.2 0.45 
Rhinoconjunctivitis 93 3.7 1.2-12 0.02 3.5 0.9-13 0.07 
Parental income of 3 or less 
on a 4-point scale 
82 3.0 0.9-9.9 0.08    
Physically active ≤ 5 
hours/week 
93 2.2 0.9-5.2 0.09    
History score* 93 2.5 1.6-4.0 <0.001    
Table 2. Regression analysis of factors in the patient history associated with PA or 
CA. PA (=1) or CA (=0) was used as a dichotomous dependent variable. Model A: 
OR was estimated for each variable, adjusted for possible confounding factors. 
Model B: The four variables that came out with a significant result in Model A 
were analysed together. *History score: The sum of the scores of all the individual 
variables included in Model A, each of which was assigned a value of 0 = no or 
1=yes. 
 
5.1.2 Clinical presentation  
Children with PA had a reduced score on the Asthma control test compared to the 
children with CA (23 (3) vs. 17 (2), p<0.001). The clinical phenotype of children with 
PA was either chronic symptoms or recurrent exacerbations with or without chronic 
symptoms between exacerbations, Figure 8. Children with chronic symptoms only had 
a reduced Asthma control test score (16 (3) vs. 20 (2), p=0.001) compared to the 
children with exacerbations only. There were no differences in age or gender 
distribution, prescribed medications, FEV1, FeNO, response to methacholine 
provocation, blood eosinophils or neutrophils or total IgE between these two groups of 
children with PA, results from analysis not shown. 
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5.1.3 Symptom triggering factors 
Children with PA reported more external symptom triggering factors (median 6/9 vs. 
4/9, p<0.001). In univariate analysis, the following triggers were more common among 
children with PA: viral infection (p=0.03), birch and grass pollen (p=0.02), humid air 
(p=0.001), cold air (p=0.001) and tobacco smoke (p=0.04). Results from the binary 
logistic regression analysis of symptom triggering factors are presented in Table 3. 
  
Exacerbations 
only 
n=19 
  Chronic  
symptoms  
only 
n=17 
Figure 8. Illustrations of the three observed clinical phenotypes of 
children with PA: Exacerbations: Children with PA who had received 
more than 1 course of oral corticosteroids during the preceding 12 
months, without experiencing daytime or night-time symptoms 
between exacerbations. Chronic symptoms: Children with PA that had 
experienced daytime and/or night-time symptoms more than 2 
times/week the preceding three months.  
Both: n=21 
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Parameter Model A 
(adjusted for age, 
gender and ethnicity) 
Model B 
(Multivariate analysis) 
 N OR 
95% 
CI 
p OR 95% CI p 
Viral airway 
infection 
93 3.6 0.99-13 0.05 4.3 0.95-19 0.06 
Birch – grass pollen 92 2.8 1.1-7.0 0.03 2.8 1.01-7.8 0.048 
Fog / humid air 90 4.9 1.8-13 0.002 4.3 1.5-13 0.01 
Cold air 93 4.2 1.6-11 0.003 3.1 1.1-8.8 0.03 
Tobacco smoke 89 2.4 0.97-6.1 0.08    
Sum of all triggers 
(trigger score)* 
93 2.6 1.7-4.1 <0.001    
Table 3. Regression analysis of factors triggering asthma symptoms in children 
with PA and CA. PA (=1) or CA (=0) was used as a dichotomous dependent 
variable. Model A: OR was estimated for each variable, adjusted for possible 
confounding factors. Model B: The four variables that came out with a significant 
result in Model A were analysed together. *Trigger score: the sum of the scores of 
all the individual triggering factors included in Model A, each of which was 
assigned a value of 0 = no or 1=yes. 
 
5.1.4 Treatment and adherence 
In line with the inclusion criteria, children with PA were prescribed more inhaled 
corticosteroids (800 (800-800) vs. 320 (200-400) µg Budesonide equivalents daily) and 
more courses with oral corticosteroids, (2 vs. 0 courses per year). Furthermore, 80% of 
children with PA were taking three controller medications (ICS, LABA, LTRA) and 
79% were inhaling SABA more than twice weekly. By comparison, 65% of the 
children with CA were taking two controller medications. With respect to adherence, 
59% and 44% of those with PA and CA, respectively, reported that they missed on the 
average less than one dose of controller medication per week (p=0.14) and 39% vs. 
51% reported that they missed 1-3 doses per week (p=0.24).  
 
5.1.5 Differential diagnosis 
The detailed assessment of each child, including nNO sampling (PA: n=49) and 
computerized tomography (n=50) did not reveal any differential diagnosis. For the 48 
children who underwent a sinus CT, the median Lund-MacKay score was 2, with 9 
children demonstrating a score > 5. 
 
5.1.6 Severely resistant to therapy vs. difficult to treat 
In attempt to identify children with PA resistant to therapy, we excluded those patients 
subjected to identified possible aggravating factors, including untreated 
rhinoconjunctivitis (n=4), current exposure to tobacco smoke (n=12), untreated 
symptoms of GERD (n=5), the presence of pets in the home despite sensitization to 
such pets (n=3), sensitization to moulds and reported exposure to a problematic and/or 
humid indoor climate (n=4). After these exclusions, 33 (61%) of the children with PA 
were defined as suffering from severe therapy-resistant asthma. These children had 
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parents with a higher income (p=0.002) and education (p=0.004) and exhibited a non-
significant trend towards higher FEV1 (86 (19) vs. 76 (18), p=0.06) and lower FeNO 
(15 (10-38) vs. 32 (16-42), p=0.06) compared to those who were difficult to treat due to 
exacerbating factors. 
 
5.2 SPIROMETRY AND METHACHOLINE PROVOCATION (I) 
 
 PA CA  p-value 
Dynamic spirometry (n)* 54 39  
FEV1, % of predicted  82 (20) 90 (11) 0.02 
FVC, % of predicted  101 (18) 103 (16) 0.60 
FEF50, % of predicted  69 (28) 85 (18) 0.002 
FEV1/FVC x 100 78 (10) 85 (7) <0.001 
    
Static lung volumes (n)  45 30  
TLC, % of predicted 106 (15) 104 (15) 0.45 
RV, % of predicted 
FRC 
133 (60) 125 (55) 0.60 
RV/TLC x 100  23 (8) 20 (8) 0.14 
FRC, % of predicted 120 (24) 111 (28) 0.20 
    
Methacholine provocation (n)
#
 32 39  
DRSmethacholine, median (IQR) 18 (1.5-65)  3 (0.4-27) 
(((0.4272727
27)27512726
.9) 
0.01 
PD20 < 2 µmol, % 69 33 0.003 
PD20 negative, % 16 31 0.14 
FEV1 post-salbutamol, % of predicted  89 (16) 92 (11) 0.44 
    
Table 4. Measurements of pulmonary function and response to provocation with 
methacholine in children with PA and CA. The values presented are means (SD), 
unless otherwise indicated. 
*Reported values are obtained before salbutamol was given. 
#
 Fifteen children with PA were not subjected to provocation with methacholine 
because their baseline FEV1 was <70% of predicted. Another 7 children with PA 
did not undergo methacholine provocation because they had taken β-2 agonist on 
the same day (n=3), because of technical problems with the equipment (n=2) or in 
accordance with the recommendation of their physician based on the severity of 
their asthma (n=2). 
 
 
5.3 ASSESSMENT OF ALLERGY 
 
5.3.1 Symptoms, allergic comorbidity and atopy (I) 
Symptoms after exposure to animal dander (65% vs. 63%, p=0.88) and food allergens 
(33% vs. 23%, p=0.28) were equally common between children with PA and CA 
whereas symptom related to birch or grass pollen exposure were more common in 
children with PA, (74% vs. 49%, p=0.02). There were no statistically significant 
differences in comorbidity with reported atopic eczema (82% vs. 69%, p=0.17), food 
allergy (70% vs. 62%, p=0.37) or anaphylactic reactions (28% vs. 39%, p=0.28), but 
comorbidity with rhinoconjunctivitis was more common in children with PA (89% vs. 
67%, p=0.01). The two groups of children also had similar levels of Total IgE (283 
 26 
(118-853) vs. 280 (66-700), p=0.51). Most of the children with PA or CA were atopic 
(82 % and 80%, respectively; p = 0.81), as assessed by Phadiatop
®
 and fx5
®
, data not 
shown.  
 
5.3.2 Component resolved allergy diagnostics (II) 
Assessment of allergic sensitization by component resolved analysis revealed similar 
results, with eighty percent of children in both groups sensitized to at least one allergen 
and children in the two groups were similarly sensitized to food allergens, pollen and 
perennial allergens, Figure 9. Sensitization towards individual allergen sources and 
specific allergens were no different between children with PA and CA (results not 
shown). The most common allergen sources in both groups of children were cat (76% 
(rFel d 1 and 4)), timothy grass (64% (rPhil 1,2,5,6 and 11)) and birch (64% (nBet v 
1)). The most common food allergy source was peanut; 42% (Ara h 1, 2, 3 and 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Sensitization patterns among children with PA and CA. Analysis 
includes allergen components of perennial aeroallergens, pollen allergens 
and food allergens: Perennial aeroallergens: Dog (rCan f 1, 2, 3, 5), horse 
(rEqu c 1, 3), cat (rFel d 1, 2, 4), mouse (nMus m 1) house dust mites (rBlo t 
5, nDer f 1, rDer f 2, nDer p 1, rDer p 2, 10, rLep d 2, rEur m 2), cockroach 
(rBla g 1, 2, 5, 7), Alternaria (rAlt a 1, 6), Aspergillus (rAsp f 1, 3, 6) and 
Cladosporium (rCla h 8). Pollen allergens: Bermuda grass (nCyn d 1), 
Timothy (rPhl p 1, 2, 4, 5, 6, 11), Alder (rAln g 1), Birch (nBet v 1), Hazel 
(rCor a 1.0101), Japanese cedar (nCry j 1), Cypress (nCup a 1), Olive 
(nOle e 1, 7, 9), Plane (rPla a 1, 2, 3), Ragweed (nAmb a 1), Mugwort (nArt 
v 1, 3), Goosefoot (rChe a 1), Wall pellitory (rPar j 2), Plantain (rPla l 1), 
Saltwort (nSal k 1) and cross-reactive markers of polcalcin (rBet v 4 and 
Phl p 7) and profilin (Latex rHev b 8, Birch rBet v 2, Timothy rPhl p 12 
and Annual mercury rMer a 1). Food allergens: Kiwi (nAct d 1, 2, 5, 8), 
Celery (rApi g 1), Apple (rMal d 1), Peach (rPru p 1, 3), Cashew nut (rAna 
o 2), Brazil nut (rBer e 1), Hazel nut (rCor a 1.0.0401, 8, 9), Walnut (nJug r 
1, 2, 3), Sesame seed (nSes i 1), Peanut (rAra h 1, 2, 3, 8, 9), Soy (rGly m 4, 
5, 6), Buckwheat (nFag e 2), Wheat (rTri a 14, a 19, nTri aA_TI), Cow’s 
milk (nBos d 4, 5, 6, 8, lactoferrin), Cod (rGad c 1), Egg (nGal d 1, 2, 3, 5), 
Shrimp (nPen m 2, 4), and cross-reactive components of tropomyosin 
(Anisakis rAni s 3, Shrimp nPen m 1). 
Controlled persistent asthma, n=39 
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A specific IgE-response to >3 single animal-derived allergens from the 
lipocalin (nMus m 1, rEqu c 1, Fel d 4, rCan f 1, 2), kallikrein (rCan f 5) and 
secretoglobin (rFel d 1) protein families was more common among children with PA 
compared to children with CA (n=14 vs. n=3, p=0.03). Among children with PA, those 
who were multi-sensitized to more than 3 single animal derived lipocalin, kallikrein or 
secretoglobin allergens demonstrated increased levels of FeNO (p=0.02), blood 
eosinophils (p=0.02) and BHR to methacholine (p=0.002) compared to children with 
PA, but positive to fewer of these components. Moreover, the multi-sensitized group 
had higher total IgE levels (p=0.006) and demonstrated a non-significant trend towards 
requiring more treatment courses with oral corticosteroids (p=0.051). 
 
5.3.3 CD-sens (III) 
We compared CD-sens in 22 cat-allergic children, 11 with PA and 11 with CA, and 
found that children with PA had higher CD-sens compared to those with CA (7.1 (3.2-
14) vs. 1.3 (0.2-4.8), p=0.02). No significant differences were observed when 
comparing basophil reactivity expressed as Max % Cat activated basophils (p=0.12), 
IgE molecules per basophil (p=0.33), FcεR1 on basophils (p=0.15) and number of 
basophils in the blood (p=0.69). There were no significant differences in IgE antibodies 
and specific IgE antibodies to cat between these two groups of children, Figure 10. 
 
 
 
 
               CD–sens              Cat IgE (kUa/L)                 IgE (kU/l) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, we found significant correlations between CD-sens and asthma control, 
markers of allergic inflammation and markers of sensitization when investigating all 
the children that were included in this analysis (n=22), Table 5. 
  
Figure 10. Comparisons of CD-sens, Cat IgE and IgE between the two groups of cat 
allergic children with PA and CA. 
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Variabel 1 Variabel 2 r-value p-value 
Asthma control test CD-sens - 0.63 0.002 * 
FeNO CD-sens 0.55 0.01 * 
Eosinophils in blood CD-sens 0.49 0.02 * 
IgE antibodies to cat CD-sens 0.63 0.002 * 
IgE antibodies to cat/ IgE CD-sens 0.57 0.005* 
IgE to rFel d 1 CD-sens 0.54 0.01* 
ICS CD-sens 0.30 0.17 
FEV1 CD-sens 0.31 0.17 
DRSmethacholine CD-sens 0.20 0.44 
Table 5. Correlations between CD-sens and various markers of allergic 
sensitization and asthma morbidity. 
 
 
5.4 ASSESSMENT OF INFLAMMATION (IV) 
 
 PA (n=57) CA (n=39)  p-value 
Biomarkers     
Total white blood cells (10
9
/L) 6.7 (2.1) 5.9 (1.4) 0.04 
Neutrophils (10
9
/L) 3.2 (1.4) 2.7 (0.7) 0.02 
Eosinophils (10
9
/L) 0.5 (0.4) 0.3 (0.2) 0.003 
Interleukin 5 (pg/ml), median (IQR) 0.32 (0-2) 0 (0-0) 0.003 
 CRP (mg/L) median (IQR) 0 (0-2) 0 (0-0) 0.14 
EPX* median (IQR) 136 (91-246) 133 (84-189) 0.32 
FeNO, p.p.b. median (IQR) 22 (10-40) 17 (9-26) 0.13 
    
Table 6. Biomarkers of inflammation from blood, urine (EPX) and exhaled air 
(FeNO) in children with PA and CA. * ng /mmol creatinine. All values givens as 
means (SD) unless otherwise stated. 
 
FeNO correlated with DRSmethacholine (r=0.40, p<0.001), Asthma control test (r=-0.27, 
p=0.007) and blood eosinophils (r=0.42, p<0.001). In addition, blood eosinophils 
correlated with DRSmethacholine (r=0.45, p<0.001) and urinary EPX (r=0.50, p=0.01).  
 
5.4.1 Extended FeNO analysis 
When adjusting for height, a difference in FeNO between children with PA and CA 
became noticeable. Children with PA had trend towards higher levels % FeNO 
compared to children with CA; 210% (101-367) vs. 139% (85-216), p=0.07, 
respectively. When analysing all children (n=96), those with % FeNO >200 (n=43, PA: 
n=30, CA: n=13) had reduced asthma control (18.5 (4) vs. 20.4 (4), p=0.04) and 
FEV1/FVC (77 (10) vs. 83 (8), p=0.004) and increased bronchial hyperresponsiveness 
(54 (5-67) vs. 2 (0.4-36), p=0.001), bronchial wall thickening on CT (25 (9) vs. 17 (6), 
p=0.004), blood eosinophils (0.5 (0.4) vs. 0.3 (0.3), p<0.001) and total IgE (539 (253-
1525) vs. 140 (43-425), p<0.001) compared to those with % FeNO <200. 
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5.4.2 Serum levels of YKL-40 and chitotriosidase activity 
YKL-40 levels and chitotriosidase activity were significantly higher in serum from 
children with PA compared to those with CA (19.1 (6.8) vs. 16.4 (3.9), p=0.01 and 67.1 
(37) vs. 51.2 (24), p=0.01, respectively), Figure 11. YKL-40 levels were higher in 
children with PA compared to healthy controls (19.1 (6.8) vs. 15.4 (8.9), p=0.04), 
whereas there was no statistical significant difference in chitotriosidase activity 
between these two groups (67.1 (37) vs. 57.9 (28), p=0.25). 
 
 
Figure 11. Comparison of serum levels of YKL-40 (A) and Chitotriosidase activity 
(B) in children with problematic severe and controlled persistent asthma. 
 
Among all children with asthma, significant correlations between YKL-40 and asthma 
control (r=-0.26, p=0.01), FeNO (r=0.21, p=0.04) and blood neutrophils (r=0.49, p < 
0.001) were observed. These correlations were more evident in the group of children 
with severe therapy resistant asthma; asthma control (r=-0.38, p=0.03), FeNO (r=0.48, 
p=0.004), and blood neutrophils (r=0.63, p=<0.001), Figure 12.  
 
5.4.3 Bronchial wall thickening  
BWT was assessed on 44 children with PA (30 children with severe therapy resistant 
asthma). In the group of children with severe therapy resistant asthma, there were 
significant correlations between YKL-40 and BWT diagnosed by HRCT (r=0.45, 
p=0.01), Figure 12.  
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5.4.4 Variations in the CHI3L1 gene and YKL-40 levels  
Children homozygous for the C allele had higher levels of YKL-40 (18.8 (16.6-22.8)), 
compared to heterozygous carriers (14.0 (12.5-17.4), p<0.001), Figure 13A. Among 
the CC carriers, children with PA had higher levels of YKL-40 compared to those with 
CA (20.9 (18.6-24.9) vs. 16.7 (15.2-18.3), p<0.001), Figure 13A. Fifty-seven percent 
of children with PA were homozygous for the C allele, compared to 72% of children 
with CA, p=0.04.  
 
5.4.5 Variations in the CHIT1 gene and chitotriosidase activity 
Children lacking the 24 bp duplication in exon 10 (75/75 bp homozygous) had 
significantly higher chitotriosidase activity compared to those heterozygous for the 
deletion (75/99 heterozygous), (72.9 (55.3-86.2) vs. 35.9 (27.7-42.5)), p<0.001). 
Among those lacking the 24 bp duplication, children with PA had higher levels of 
chitotriosidase compared to those with CA (76 (66-107) vs. 58 (52-73), p=0.001), 
Figure 13B. Sixty-three percent of children with PA were lacking the 24 bp duplication 
in exon 10 (75/75 bp homozygous) compared to 68.4 % of children with CA, p=0.77. 
r= 0.63 r= 0.45 
Figure 12. Correlations between YKL-40, neutrophils and bronchial wall 
thickening among children with severe therapy resistant asthma. 
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Figure 13. The effect of genetic variability on chitinase levels in all asthmatic 
subjects. A) Serum YKL-40 levels according to CHI3L1 rs4950928 genotype. B) 
Serum chitotriosidase activity according to CHIT1 rs3831317 genotype. Grouped 
results from children with CA () and PA (). Results are displayed as 
individual data points with median bars. 
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6 DISCUSSION 
  
6.1 GENERAL COMMENTS REGARDING METHODS 
 
6.1.1 Study design 
In this observational study, the main objective was to provide a detailed 
characterization of Swedish children with Problematic severe asthma (PA), and 
investigate how children with PA differ from age matched peers with persistent, but 
controlled asthma (CA). PA is uncommon in children and a multi-centre approach was 
needed to acquire a sufficiently large group of children. No power calculations were 
performed beforehand, since our intention was to identify as many children as possible 
by a survey of 27 pediatric clinics throughout Sweden. Our cohort of 57 children with 
PA is larger than most (14, 27, 40, 131), but not all (43) studies with a similar design 
investigating severe childhood asthma. This might appear to be a low number 
compared to population based studies with several hundreds or thousands of children 
with asthma. However, a major advantage of this study is the vast amount of 
information gathered from each individual child, providing a meticulous 
characterization and making it possible to explore associations and disease mechanisms 
in relation to the presenting phenotype. 
The different stages of this project were carried out in cooperation with 
several clinicians and researchers within this field. Paediatric allergists from paediatric 
centres throughout Sweden were involved in the development of the study protocol. 
The actual data collection, on the other hand, was performed by a mobile team 
consisting of two individuals only (myself and Björn Nordlund). We visited all the 
participating clinics and conducted the interviews and the majority of the procedures on 
site, utilizing brought equipment, which ensured the standardization of patient inclusion 
and collection of biological samples. An extensive network of basic researchers at 
Karolinska Institutet has been engaged in conducting analyses of the samples obtained 
within the areas of allergy, inflammation and genetics. 
This study is cross-sectional in the sense that the children only were 
investigated once, but not in the sense that the included children were extracted from a 
population based study; accordingly this project was not designed to estimate the 
prevalence of severe childhood asthma in Sweden. Nevertheless, the children were 
broadly recruited, allergists at 27 hospital based pediatric clinics were invited to refer 
children to this study, and although 11 of these clinics are not represented, it is our 
interpretation that the children referred, represent the most challenging asthmatic 
children throughout Sweden.  
Furthermore, this project could be classified as a comparative study with 
a case-control like design as we were comparing asthmatic subjects with problematic 
severe disease (the 'cases') with patients who did not have problematic severe disease, 
but were otherwise similar (the controls) (132). One advantage of this study design is 
the possibility to study multiple exposures associated with rare diseases simultaneously, 
whereas the major drawbacks are that only associations can be studied and recall bias 
might be a problem. 
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6.1.2 Criteria of inclusion and definitions 
Detailed inclusion criteria are a prerequisite in case-control studies to ensure that the 
subjects studied are representative of all subjects with the investigated disease. In this 
project, all subjects were included on the basis of strictly defined criteria, with myself 
and the principal investigator taking sole responsibility for the final inclusion. Of the 70 
children with PA referred for participation in the study, 13 were not included. Eight of 
these children did not fulfill the minor criteria regarding medications and symptoms / 
asthma control. The remaining 5 children had other diagnosis (born prematurely, 
immunodeficiency, major pulmonary surgery), diagnosis which could contribute to 
their symptoms. 
Moreover, our observations concerning heredity (27), socioeconomic 
factors (133), health care (20), triggering factors (25), lung function (27, 134-135) and 
BHR (14) are comparable to those of previous studies. The frequency of atopic 
sensitization observed here is similar to that in the Childhood asthma management 
program (CAMP) study (134), as well as with preliminary findings in children with 
persistent asthma recruited from a large Swedish birth cohort (136) upon follow-up at 8 
years of age (Inger Kull, PhD, personal communication, April 2010). Finally, the 
characteristics of our children with PA and CA agree well with the findings from a 
population-based study in Norway (14). Taken together, these considerations indicate 
that our subjects were representative of children with varying manifestations of 
persistent asthma. 
The current definition of PA aims at including children who have poor 
asthma control despite high doses of inhaled corticosteroids. Asthma control is defined 
as “to which extent the manifestations of asthma have been reduced or removed by 
treatment” (15), a concept that not only includes the assessment of daytime and 
nocturnal symptoms, and the need for reliever medication, but also an estimation of 
future risk of severe exacerbations. Hence, the inclusion criteria for children with PA in 
this study combine an evaluation of medication, chronic symptoms and exacerbations. 
These inclusion criteria were developed from the GINA guidelines (12), in consensus 
with the Allergy section of the Swedish Pediatric Society and are similar, but not 
identical, to the inclusion criteria in other studies on severe childhood asthma (27, 40, 
43).  
It is noteworthy that specific biomarker criteria are not included in the 
current definition of PA, and the reason for this is the pathophysiological heterogeneity 
of asthma, as described in the introduction. This heterogeneity was confirmed in a 
cluster analysis to identify phenotypes in 161 asthmatic children with different 
manifestations of asthma (89 children with severe asthma) (19). Four clusters were 
identified based on 12 variables including demographic data, duration of asthma, FEV1 
pre and post salbutamol, atopy, exhaled nitric oxide and medication. Children classified 
as severe asthmatics were present in all clusters, which confirms the heterogeneity of 
the disease. 
In the Swedish severe asthma study, inclusion criteria based upon 
biomarkers would have provided different results, as exemplified with the extended 
FeNO analysis (section 5.4.1). The current definition is a reflection of how children 
with PA present to the pediatric allergist, i.e. having troublesome symptoms, despite 
prescription of maximum doses of conventional medications, and is in agreement with 
the recent WHO definition of severe asthma (29). 
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6.1.3 Control group 
The selection of controls is particularly crucial for the validity of a case-control study, 
and in this project two aspects regarding the controls deserve comment. First of all, it 
must be emphasized that children in the control group are not mild asthmatics; they all 
have persistent asthma but achieve acceptable symptom control with continuous 
treatment with a low to moderate dose of inhaled corticosteroids. By making 
continuous treatment with inhaled corticosteroids inclusion criteria for the control 
group, we avoided investigating differences caused by steroid treatment per se. 
Secondly, and rather surprisingly, children with CA were more difficult 
to identify and recruit to this study than the children with severe asthma, and as a 
consequence, less children with CA were included, and the majority were recruited 
from the Stockholm region. There are several explanations for this; children with 
controlled asthma do not need to visit a paediatric allergist at a hospital based clinic, 
therefore the allergists involved in this study had few patients of this category on their 
listings. Once identified, children with controlled asthma are also less motivated to 
undergo the extensive study protocol. Besides, many asthmatic children with adequate 
control of their symptoms discontinue their treatment with ICS and were therefore not 
even considered for inclusion.  
  
6.1.4 Adherence to treatment 
Reliable assessment of adherence to prescribed treatment is a challenge in clinical 
practice as well as in research on patients with asthma. In this study, adherence was 
determined by self-assessment and this information might be somewhat unreliable. The 
reliability might have been improved by, for example, examining pharmacy records. 
Nonetheless, the approach employed in this study represents current clinical practice in 
Sweden and the lack of any differences in adherence between the groups (PA vs. CA or 
children who were severely resistant to therapy vs. those who were difficult to treat due 
to aggravating factors) suggest that this shortcoming did not exert any major impact on 
our findings. 
 
6.2 CLINICAL CHARACHTERISTICS (I) 
6.2.1 Family history and comorbidity 
The current dataset indicates that a child with PA is more likely to have parents who 
smoke and have asthma, come from underprivileged circumstances and have untreated 
rhinoconjunctivitis, compared to a child with controlled asthma compared to a child 
with CA. Although this study was not designed to establish causality, there are 
plausible biological explanations to support that some of these observations are 
involved in the development of PA. 
Regarding heredity, there is good evidence that inherited factors influence 
the risk of developing childhood asthma, and numerous candidate genes have been 
identified (137). In addition, a few genes have been associated with asthma severity, 
one example is mutations in the interleukin-4 receptor alpha gene, which regulates Th2 
responses (138). The search for other genetic variants, possibly related to PA, is 
currently being conducted based on samples from the Swedish severe asthma study. 
Furthermore, with respect to parental smoking, prenatal exposure to 
tobacco smoke influences lung function at birth (139), smoking is associated with 
steroid resistance (140) and passive smoke exposure, measured by urinary cotinine 
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levels, has been associated with more exacerbations, increased airflow obstruction and 
increased BHR (141). 
The comorbidity between childhood asthma and rhinoconjunctivitis is 
well established (142). However, the observation that patients with PA report clinical 
symptoms of rhinoconjunctivitis more often than those with CA has only been reported 
in adults (143), which is in concordance with the concept of the united airways (144). 
 
6.2.2 Clinical presentation 
Three main clinical phenotypes were identified among the children with PA; children 
with exacerbations only, children with chronic symptoms only and children with both 
exacerbations and symptoms. As expected, those with chronic symptoms had a reduced 
score on the asthma control test compared to those with exacerbations only, but the fact 
that no differences were found with respect to prescribed medication, pulmonary 
measurements, bronchial hyperresponsiveness and biomarkers of inflammation 
indicates that these two groups of children have equally severe asthma, although the 
clinical presentation differs, and this finding is in line with the proposals from the 
PSACI group (18). 
 
6.2.3 Difficult to treat asthma vs. therapy resistant asthma 
Of all included children with PA, forty percent were exposed to exacerbating factors 
that could be treated, or at least partially eliminated. This finding provides support for 
the clinical utility of the recently formulated definition of PA. Moreover, it shows that 
the fundamental effort of taking a detailed history is helpful in identifying children with 
the most severe asthma. However, home visits (145) and assessment of steroid response 
with for example Triamcinolone injection (43) could have further improved the 
classification of children with PA.  
The results indicate that children with PA, a low socioeconomical 
background and high FeNO have an increased probability of suffering from asthma 
which is difficult to treat because of identifiable aggravating factors. This suggests a 
shortcoming of the profession to educate these families on how to avoid or handle 
triggering factors, and furthermore, a high FeNO is a useful hint of increased risk of 
exacerbating factors in these children. However, it should be kept in mind that these 
children might still have severe symptoms after the exacerbating factors are dealt with. 
Children classified as having severe therapy-resistant asthma might 
benefit from more invasive procedures, such as bronchoscopy, that provide a more 
detailed characterization of their disease, e.g. identification of bacterial infections 
which would justify treatment with macrolides (146). In addition, they could be 
candidates for novel therapeutic options, such as anti-IgE treatment and to participate in 
studies on other treatment alternatives currently in the pipeline, including Pitrakinra 
(IL4-/IL-13 antagonist) (147), Lebrikizumab (IL13 antagonist) (148) and Reslizumab 
(antibody against IL-5) (149). Finally, future studies on the underlying mechanisms of 
severe childhood asthma should only include children diagnosed with therapy resistant 
asthma. In Paper IV we provide an example of the usefulness of this classification in 
the analysis of correlations between chitinases and other features of asthma; 
correlations were most evident among children classified as being therapy resistant. 
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6.2.4 Statistical considerations  
It should be noted that no correction for multiple testing has been performed in paper I. 
Such correction would have resulted in fewer statistically significant differences 
between these two groups of patients. Furthermore, this study was not designed for 
powerful regression analysis, but the results from the analysis conducted, are useful to 
generate hypothesis of which factors could be most important.  
 
6.3 ASSESSMENT OF PULMONARY FUNCTION (I) 
The most noteworthy finding regarding pulmonary function is the modest difference in 
FEV1 between children with PA and CA, a finding which is in line with findings in 
other studies (14, 16, 27). There are several possible explanations for this finding; FEV1 
is a measurement of airflow in the larger airways, but it is insensitive to changes in the 
smaller airways, and symptoms in patients with severe asthma might be caused by 
small airway obstruction (150). Furthermore, measurements of pulmonary function 
correlate poorly with the distribution of inflammation in the airways (151). Finally, 
since we have investigated children, the decline in lung function is still not as 
pronounced as that observed in the adult population (25-26). However, it should also be 
noted that the children with CA do not have an entirely normal pulmonary function, 
due to the fact that the control group does not consist of mild asthmatics. 
Looking at FEF50 and FEV1/FVC, the difference between the two groups 
of children appears to be more robust. The reasons for this could be that FEF50 is a 
better indicator of obstruction in smaller airways and that FEV1/FVC reflects 
exaggerated dysanapsis, i.e. the disproportionate growth of airways and lung 
parenchyma, in severe asthmatics (16). All observations regarding pulmonary function 
are in line with the findings from a more thorough analysis of pulmonary function in 
severe asthmatic children, partly based on patients from the Swedish Severe asthma 
study (135).  
 
6.4 BRONCHIAL HYPERRESPONSIVENESS (I) 
Children with PA had increased BHR compared to children with CA which support 
findings from previous studies (27) can could provide an explanation to why children 
with PA are reporting more symptom triggering factors. Somewhat surprisingly, there 
were 5 children with PA who did not respond to a provocation with methacholine, 4 of 
these children were not sensitized to any allergen (results not shown), which support 
findings in a similar study (14). The explanations could be that the high doses of 
inhaled corticosteroids suppress the methacholine response or that these particular 
individuals constitute a specific phenotype. In addition, it should be noted that 
sensitivity to methacholine could be reduced in non-atopic compared to atopic children 
(152).  
 
6.5 ASSESMENT OF ALLERGY (I, II) 
The majority of children in both groups were atopic and there were no differences 
between the two groups when comparing allergic sensitization to allergen sources or 
individual specific allergens. Previous studies have found that being allergic increases 
the risk of having persistent asthma in childhood (134), but studies on allergic 
sensitization in relation to asthma severity have provided conflicting results. Siroux et 
al. found that the type and intensity of the allergic sensitization were not associated 
with any criteria of asthma severity in 216 asthmatic children (153). On the other hand, 
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Carroll et al. found significant associations between asthma severity score and Total 
IgE and in 400 asthmatic children (154). Ponsonby et al. also found that there are more 
atopic children with severe asthma (155). Furthermore, in the Fitzpatrick study from 
2006 (27), which is similar to the Swedish severe asthma study in power and design, 
atopy was more prevalent in the severe asthma group. However, it should be noted that 
the major allergens in the Fitzpatrick study were house dust mites and weed mix, 
allergens which are rarely found in Sweden. Regarding sensitization to animal dander, 
tree and moulds, there were no differences between severe and mild asthmatics in the 
Fitzpatrick study either.   
With the help of component resolved diagnostics, we were able to 
demonstrate that sensitization to more than 3 single allergens from the lipocalin, 
kallikrein and secretoglobin protein families (allergens from cat, dog, horse and mouse) 
was more common among children with PA compared to those with CA. Multi-
sensitization to these allergens was also associated with evidence of increased 
eosinophilic bronchial inflammation and a trend towards a greater number of oral 
corticosteroid courses and thus making this appear to be a clinically relevant finding.  
From a clinical point of view, we interpret the association between 
increased bronchial inflammation and multi-sensitization to lipocalin, kallikrein and 
secretoglobin allergens as a consequence of ubiquitous exposure to furred animals or an 
increased disposition for allergic disease. We have previously shown that cat dander is 
easily transferred from cat owner’s into school environments where it significantly 
affects asthmatic children (98). It is crucial to control the inhalation of animal-derived 
lipocalin, kallikrein and secretoglobin allergens in dander particles as they are small in 
size and easily deposited in the respiratory tract. To date, only interventions involving a 
high-altitude environment (156) or temperature-controlled laminar airflow during sleep 
(Protexo) (157), have proven effective in this respect. 
 
6.5.1 CD-sens (III) 
In Paper III we explored the relationship between basophil allergen threshold 
sensitivity (CD-sens) and clinical parameters in 22 cat allergic children, of whom 11 
had PA. We used CD-sens as a measure of allergen sensitivity and found that basophils 
from children with PA were significantly more sensitive to cat-allergens, compared to 
basophils from children with CA. Furthermore, CD-sens correlated with several other 
characteristics of asthmatic disease, including asthma control, IgE antibodies and 
biomarkers of allergic inflammation.  
A high CD-sens implies that lower allergen concentrations are needed to 
activate basophils, and presumably the mast cells, which subsequently leads to the 
initiation of allergic inflammation. However, recent evidence indicates that basophils 
are not only markers of mast cell function but could also function as initiators of 
allergic inflammation and contribute to the development of chronic allergic 
inflammation (110). It may therefore be speculated that the higher allergen sensitivity 
in children with PA could be due to skewing of a basophil phenotype since basophils 
are a heterogeneous cell population with varying degranulation properties depending on 
the genetic background and surrounding cytokine environment at the stage of basophil 
precursor development (158).  
Once matured, basophils require on average a cross-linking of 2000 IgE-
FcεR1 complexed molecules before intracellular signalling is initiated, but there are 
considerable variations from this mean value (159). Thus, another hypothesis is that 
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basophils in children with PA need fewer cross-bindings to be activated and start 
intracellular signalling. A third possible explanation to the observed difference in 
basophil activation involves a variation in intracellular regulatory mechanisms. The 
enzyme PI3-kinase is involved in the fusion of basophil granules to the plasma 
membrane (160) and individual variation in the activity of this enzyme could also be an 
explanation for the observed differences in CD-sens.  
Once activated the basophils release their histamine containing granulae, 
containing IL-4 and IL-13 (160). These pro-allergenic cytokines induce IgE synthesis 
in B-cells and this could explain the observed correlations between a high CD-sens and 
IgE antibodies to cat and Fel d 1.  
This is the first report of the potential clinical usefulness of analysing 
CD-sens in children with severe allergic asthma. The findings indicate that children 
with PA are more sensitive to cat allergen compared to children with CA and this 
finding is of particular interest since there were no significant differences in markers of 
cat sensitization between these two groups of children. CD-sens represents the in-vivo 
pathway leading to symptoms after allergen exposure and therefore provides additional 
information compared to the assessment of sensitization alone. As it is well known that 
most children, regardless of whether they own a cat, are exposed to cat-allergens at 
school and/or at home (161), a high allergen sensitivity may therefore explain why it is 
more difficult to achieve symptom control in some cat-allergic children with persistent 
asthma. Collectively, our findings suggest that CD-sens is more closely related to the 
clinical presentation of allergic asthma than the atopic status and therefore has the 
potential to be a useful marker of disease severity. 
However, it should be noted that CD-sens is still a staff-intensive analysis 
and only can be performed in specialized laboratories. Furthermore, CD-sens varies 
between different allergens which could be because of lack of standardization in the 
allergen extracts used and finally, no reference values have been established. The 
results should probably be interpreted in a categorical manner because CD-sens>0 
signifies activation of the allergic inflammation (162), although in the current study, we 
have demonstrated that cat allergic children with PA, at a group level, have higher CD-
sens compared to those with CA. 
 
6.5.2 Potential applications of CD-sens (III) 
Assessment of allergen sensitivity is not only useful for investigating the severity of a 
child´s asthma, it could also be useful for selecting those with the highest allergen 
sensitivity who are likely to benefit most from more extensive treatment alternatives 
such as anti-IgE treatment (Omalizumab). Omalizumab binds to the Fc portion of 
circulating IgE and prevents IgE binding to the FcεRI and FcεRII on mast cells and 
basophils, thereby inhibiting activation of these cells (163). The clinical effect of this 
treatment in patients with severe allergic asthma has been demonstrated in several 
studies (164). The selection of patients, and the timing and dosing of Omalizumab 
injections are currently only based on the presence of severe allergic asthma and by 
measurement of total IgE and weight.  
This is the first biomarker guided treatment option in asthma, but still, 
only one third of patients treated with Omalizumab experience a considerable 
improvement following this treatment (165). Biomarkers to improve the selection of 
responder from non-responders have not yet been established (163), although CD-sens 
has been shown to be useful in the monitoring of anti-IgE treatment efficiency (112) 
   39 
and to correlate with the response to a bronchial allergen inhalation challenge (113). 
Thus, studies examining the capability of CD-sens to identify Omalizumab responders 
are warranted as CD-sens is a biomarker of the key pathological process related to 
Omalizumab treatment. Furthermore, CD-sens could be evaluated as a biomarker to 
select candidates for other established (subcutaneous immunotherapy) and novel 
immunomodulatory treatment alternatives.  
 
6.6 ASSESSMENT OF INFLAMMATION (IV) 
We found increased levels of blood neutrophils, blood eosinophils and serum IL-5 in 
children with PA which is in line with findings from adult severe asthmatics (166). The 
assessment of inflammatory biomarkers in blood will be extended with analysis of a 
broad assay of specific interleukins from these patients.  
With respect to FeNO and EPX, we found no difference between the 
groups, which questions the value of these parameters as markers of the severity of 
asthma. In light of the high degree of self-reported adherence to medication, it is 
possible that the high doses of inhaled corticosteroids used by children with PA may 
have suppressed differences in the FeNO and EPX values that might have been seen 
without such treatment.  
However, when normalizing FeNO values against the individual child´s 
height, the difference between PA and CA was more apparent. Comparing asthmatic 
children with % FeNO >200 to children % FeNO <200, irrespective of pre-determined 
severity classification, the former group had increased morbidity. This finding point to 
a clinical usefulness of FeNO measurement across all ranges of asthma severities and 
supports similar analyses performed in adults (49). 
One limitation regarding the assessment of inflammation is that the 
presented inflammatory biomarkers were assessed in blood, urine and exhaled air only 
and not more invasively by the analysis of sputum, BAL fluid or biopsies. Sputum 
induction was, in fact, part of the protocol in this project. Unfortunately, no reliable cell 
counts could be performed due to contamination of the samples with saliva and 
epithelial cells, which was verified by analysis of amylases in the sputum supernatant 
(results not shown). This shortcoming confirms the challenging nature of more invasive 
assessments of inflammation in asthmatic children and underlines the need for 
minimally invasive biomarkers.  
From this perspective, the finding of increased levels of YKL-40 in 
children with PA and the correlation between YKL-40 and bronchial wall thickening is 
particularly interesting. The current findings of increased serum YKL-40 levels in 
children with PA and the inverse correlation between YKL-40 and asthma control 
confirm and extend previous observations made in Chinese, French and North 
American cohorts of adult patients with asthma (92, 167). 
Our findings strengthen the view that YKL-40 is a marker of remodelling 
or even somehow involved in the remodelling processes. Chupp et al. found a 
correlation between serum and BAL levels of YKL-40 and RBM thickness (92) and 
interestingly, YKL-40 binds to collagen I and can regulate the formation of collagen 
fibrils (168). YKL-40 has also recently been shown to increase the proliferation and 
migration of human bronchial smooth muscle cells (169). In relation to other diseases 
also characterized by chronic inflammation and tissue remodelling, YKL-40 has been 
shown to play a role in fibrosis and angiogenesis by regulating the survival, adhesion, 
migration and proliferation of various structural cell types (93). Thus, the relation 
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between YKL-40 and asthma severity could, in part, be mediated by the effects of 
YKL-40 on fibrosis and smooth muscle cells (170). 
The role of BWT assessment by HRCT as a surrogate marker of chronic 
inflammation or airway remodelling deserves further comment. The correlation 
between RBM and BWT in children is weak (78) and has not been confirmed in all 
studies (77). However, it should be emphasized that the image of thickened bronchial 
walls represents not only the increased thickness of the reticular membrane, but 
probably also other features of remodelling; hypertrophy and hyperplasia of the 
bronchial smooth muscle, myofibroblastic proliferation, increased numbers and size of 
the mucus glands and angiogenesis (71).  
Another noteworthy finding regarding the chitinases is the close 
correlation between YKL-40 and blood neutrophils. Previous studies have indicated 
that YKL-40 is produced by a number of cells, including epithelial cells and alveolar 
macrophages (171). It is also known that YKL-40 can be stored in the specific granules 
of neutrophils and released upon activation of these cells (172). A recent study of 
sputum YKL-40 levels in adults with asthma also demonstrated a strong correlation 
with sputum neutrophil count (173). The results from our study support and extend 
these findings, by indicating that neutrophils are major producers of YKL-40 
particularly in severe asthma.  
Variation in the CHI3L1 gene was strongly associated with serum YKL-
40 levels. Children homozygous for the C-allele had higher levels of YKL-40 despite 
the fact that there were more children with CA with this genotype. However, the 
highest YKL-40 levels among CC-carriers were predominantly found in children with 
PA, demonstrating that YKL-40 levels are associated with asthma severity, irrespective 
of variations in CHI3L1. Genetic variants in the CHI3L1 gene have been associated 
with several phenotypes of asthma (174-176) although our sample size limits the 
possibility to draw firm conclusions about risk estimates related to PA and CA. In 
2008, Ober et al. found a relationship between the CHI3L1 polymorphism -131 C/G, 
circulating YKL-40 levels, prevalence of asthma and pulmonary function (94). 
Furthermore, a large population based study by Rathcke et al., including over 6500 
subjects demonstrated that the rs4905928 G allele, and not the C allele was associated 
with asthma. Taken together, there is a need for further studies investigating the 
complex genetic associations between CHI3L1 and asthma (175).
 
 
Variations in the CHIT1 genotype affected chitotriosidase activity. 
Children lacking the 24 bp duplication in exon 10 (75/75 bp homozygous) had the 
highest chitotriosidase activity compared to the 75/99 bp heterozygous and the 99/99 
homozygous genotype. Within the 75/75 bp homozygous genotype, children with PA 
had the highest chitotriosidase activity, confirming that chitotriosidase activity is 
associated with asthma severity, independently of variations in the CHIT1 gene. 
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7 MAIN RESULTS AND CONCLUSIONS 
 
A comprehensive and standardized clinical assessment discerns specific features of 
children with Problematic severe asthma (PA) and allows the identification of those 
who are severely resistant to therapy.  
 
The major distinguishing features of children with PA involve familial background 
(heredity, socioeconomic status), clinical presentation (comorbidities and triggering 
factors) and pathophysiological differences including degree of airway obstruction, 
bronchial hyperresponsiveness and inflammatory profile (IL-5, number of eosinophilic 
and neutrophilic cells in blood). 
 
Multi-sensitization towards animal-derived lipocalin, kallikrein and secretoglobin 
allergens is more common in children with PA, compared to those with controlled 
asthma (CA) and is associated with increased bronchial inflammation. 
 
Cat-allergic children with PA have a higher allergen sensitivity, as measured by CD-
sens, compared to cat-allergic peers with CA. Furthermore, CD-sens correlates with 
clinical markers of asthmatic disease, including asthma control and biomarkers of 
eosinophilic inflammation. 
 
YKL-40 levels and chitotriosidase activity are increased in the serum of children with 
PA, and YKL-40 specifically correlates with airway remodelling (assessed by HRCT) 
and blood neutrophils in children severely resistant to asthma therapy. The associations 
between YKL-40, chitotriosidase activity and asthma severity persisted after adjusting 
for variations in the CHI3L1 and CHIT1 genes, respectively. 
 
In summary, we have provided a detailed characterization of children with PA in 
Sweden, and identified potential explanatory factors for their severe disease. 
Furthermore, we examined the usefulness of two novel diagnostical methods for allergy 
and found that these methods both provide relevant information when investigating 
children with PA. Our findings support that YKL-40 is a potential biomarker of asthma 
severity and airway remodeling in children with PA. Finally, a translational research 
approach is necessary when investigating associations between etiologies, mechanisms 
of disease and clinical presentation in complex diseases. 
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8 FUTURE PERSPECTIVES 
 
The scientific community seems to have agreed upon the current definition of 
Problematic severe asthma and new studies using this definition are continuously being 
published. International collaborations are being established; one example of which is 
the European U-Biopred (Unbiased BIOmarkers for the Prediction of Respiratory 
Disease) study which our research group is participating in. The American SARP study 
(Severe asthma research program) is being continued and extended to include more 
children (177). Future reports from these projects will hopefully provide additional 
insights into the stability of the severe asthma phenotype, the mechanisms involved in 
the development of severe asthma, and novel therapeutic approaches in these children.  
One particular point of interest is characterization of the inflammatory 
pattern in the peripheral parenchyma, as inflammation in severe asthma may 
predominantly be associated with peripheral airways. Sputum samples, BAL fluid and 
transbronchial biopsies do not necessarily reflect inflammation in the lung parenchyma. 
Several methods are being developed and introduced which can help to elucidate the 
role and distribution of peripheral airway inflammation, including the measurement of 
FeNO at different exhalation flow rates. Novel imaging techniques, for instance 
magnetic resonance imaging to identify ventilation defects and molecular imaging 
techniques that enables visualisation of areas of inflammation (178) will probably also 
enhance our understanding of this disease. 
The pursuit for specific biomarkers to characterize asthma will continue, 
the goal being to find easily attainable biomarkers that will help us to understand 
disease mechanisms, select appropriate treatments and monitor the effect of these 
treatments. During the past few years, several new therapeutic alternatives have been 
developed which are increasingly being used in clinical practice (Anti IgE, 
temperature-controlled laminar airflow). Several new treatment alternatives are in the 
pipeline, including Pitrakinra (IL4-/IL-13 antagonist) (147), Lebrikizumab (IL13 
antagonist) (148) and Reslizumab (antibody against IL-5) (149) all of which 
predominantly target allergic asthma. As these are, or are likely to be, expensive 
treatment alternatives, detailed characterization of patients in order to identify those 
most likely to benefit from these interventions will be increasingly important. As 
mentioned in the discussion CD-sens could turn out to be a valuable tool in this regard, 
and the possible availability of CD-sens as a chip based method in the foreseeable 
future would make this method more easily applicable.  
Another novel marker of potential clinical relevance is periostin, a protein 
suggested to be a marker of excessive Th2-type inflammation in asthma (179) and the 
expression of periostin in airway epithelial cells is regulated by interleukin 13 
(180).The effect of Lebrikizumab treatment has been shown to be greater in severe 
asthmatics with high periostin levels compared to those with low periostin levels, as 
demonstrated by an improvement in FEV1 and reduction in FeNO) (148) thus providing 
an entirely new example of biomarker guided treatment in severe asthma. Periostin 
might also turn out to be a useful biomarker for other treatment alternatives.  
However, the most likely scenario regarding biomarkers is that it is no 
single biomarker will characterise asthma but rather a set or a cluster of different 
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biomarkers (61), and he most useful of all will probably be clusters of markers 
combining genomics, transcriptomics and proteomics. 
New treatment alternatives for asthma should probably not only focus on 
suppressing the inflammatory response. The idea of primary prevention of asthma is 
becoming an option (54) and in this regard combining vaccines for allergy and 
rhinovirus infections are a novel and interesting approach (181). Another novel 
approach is intralymphatic immunotherapy which might turn out to be a “fast-track”, 
effective alternative to subcutaneous immunotherapy (182). In addition, Vitamin D 
supplementation could be a straightforward treatment alternative to strengthen the 
immune response in children with therapy resistant asthma (183), although more trials 
are needed.  
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9 SAMMANFATTNING PÅ SVENSKA 
 
Astma hos barn kännetecknas av luftrörsinflammation och av att överkänsliga luftvägar 
drar i hop sig på ett sådant sätt att flödet av luft in och ut ur lungorna försämras. Detta 
ger andfåddhet, hosta och slembildning och kan påverka det drabbade barnets hälsa 
även i vuxen ålder. Upp till 13% av skolbarn rapporterar symtom på astma och ca 7% 
har läkardiagnostiserat astma. De flesta barn har god effekt av befintlig 
astmabehandling, men en mindre grupp, ca 5% av alla barn med astma, har en mer 
svårbehandlad sjukdom och uppnår inte tillfredställande kontroll på sina symtom trots 
höga doser av astmamediciner. Dessa barn har problematisk svår astma och har antigen 
kroniska, närmast dagliga symtom och/eller återkommande svåra exacerbationer. Barn 
med problematisk svår astma kan få kvarstående lungförändringar, har en hög 
sjukvårdskonsumtion och inte sällan betydande biverkningar av höga medicindoser. 
Barnen kan vara svåra att behandla därför att förutsättningarna för deras 
astmabehandling inte är optimala. Det kan bero på nedsatt följsamhet till behandling, 
otillfredsställande inhalationsteknik, pågående allergenexponering eller annan 
miljöexponering. I de fall man inte hittar någon förklaring till barnens svåra symtom, 
bedöms deras astma som terapi resistent. 
I denna avhandling redovisas resultat från en svensk multicenter studie i 
vilken skolbarn med problematisk svår astma har jämförts med jämngamla barn som 
har kronisk astma och god effekt av sin astmabehandling (kontrollerad astma). Syftet 
med studien var att göra en detaljbeskrivning av barn med problematisk svår astma, 
identifiera eventuella undergrupper och studera skillnader mellan barn med svår astma 
och barn med kontrollerad astma avseende ärftlighet, sjukdomsorsak, 
sjukdomsmekanismer och den kliniska presentationen av sjukdomen. Vidare ville vi 
utvärdera nyttan av nya biomarkörer for svår astma. 
Barnen, som rekryterades från 16 barnkliniker i Sverige, fick svara på 
frågeformulär, göra lungfunktionsmätningar, test bronkial hyperreaktivitet, lämna urin 
prov och blodprov för analys av inflammationsmarkörer (däribland vita blodkroppar 
och chitinaser i serum), genetisk kartläggning och allergitester 
(allergenkomponentanalys och basofil känslighetstest (CD-sens). Barnen med svår 
astma fick dessutom genomgå datortomografi av lungor och bihålor. 
I det första delarbetet fann vi att av 57 inkluderade barn med 
problematisk svår astma kunde 23 klassificeras som svårbehandlade, och övriga 34 var 
terapi resistenta. Barnen med problematisk svår astma skilde sig signifikant från de 
med kontrollerad astma avseende familjebakgrund (ärftlighet for astma, socioekonomi), 
klinisk presentation (astmakontroll, samsjuklighet med rhinokonjunktivit och 
symptomutlösande faktorer) och patofysiologiska mekanismer (lungfunktion, 
hyperreaktiva luftrör och inflammatorisk profil i blodet (vita blodkroppar, IL-5, 
chitinaser)). Således har vi med ett icke-invasivt protokoll som inkluderade en 
standardiserad och detaljerad klinisk karakterisering hittat särskilda kännetecken hos 
barnen med problematisk svår astma som möjliggjorde identifiering av barn med terapi 
resistent astma. 
I det andra delarbetet analyserade vi förekomsten av antikroppar mot 111 
specifika allergen hos alla barn i studien. Det var ingen skillnad i sensibilisering mot 
enskilda allergenkällor. Barnen med problematisk svår astma var oftare 
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multisensibiliserat mot flera än 3 specifika allergen från pälsdjur jämfört med barn med 
kontrollerad astma. Vi fann också att barnen med problematisk svår astma som var 
sensibiliserade mot fler än 3 av dessa allergen, hade tecken på ökad inflammatorisk 
aktivitet i blod och utandningsluft och mer hyperreaktiva luftrör jämfört med svåra 
astmatiker utan denna multisensibilisering. Detta arbete visar att det kan ha ett 
mervärde att analysera specifika allergener hos barn med svår allergisk astma jämfört 
med traditionell allergidiagnostik som mer är riktad mot allergenkällor. Vidare, att 
multisensibilisering mot fler än 3 specifika pälsdjurallergen kan vara drivande för den 
allergiska inflammationen i en undergrupp av barn med svår astma. 
I det tredje delarbetet undersökte vi om katt-allergiska barn med svår 
astma hade ökad känslighet för katt, utvärderat med allergenstimulering på isolerade 
basofiler (basofil känslighetstest, CD-sens). I denna analys inkluderades 11 katt-
allergiska barn med problematisk svår astma som jämfördes med 11 katt-allergiska 
barn med kontrollerad astma. Vi fann att barnen med problematisk svår astma hade 
signifikant högre CD-sens jämfört med kontrollbarnen och att värdet av CD-sens 
korrelerade med graden av astmasymptom, specifika IgE antikroppar mot katt och 
kväveoxid i utandningsluften, en markör för eosinofil luftvägsinflammation. Vi 
konkluderade att kattallergiska barn med svår astma har ökad känslighet för katt, och 
att detta kan vara en bidragande orsak till dessa barns svåra och kroniska symtom. Vi 
föreslår också att CD-sens skulle kunna användas som en markör för att identifiera barn 
med den svåraste allergiska astman som har störst nytta av nya, intensiva 
behandlingsinsatser så som anti-IgE behandling. 
Syftet med det fjärde arbetet var att jämföra nivåerna av ett chitinase likt 
protein YKL-40 och chitotriosidase hos patienter med problematisk svår och 
lättbehandlad astma, samt att identifiera eventuella samband mellan YKL-40, kroniska 
luftrörsförändringar (utvärderat med skiktröntgen) och andra markörer för 
astmasjukdomen.  
I nuläget saknas biomarkörer för att tillförlitligt identifiera och 
karakterisera barn med svår astma. Chitinasen YKL-40 har nyligen visat sig vara 
associerad till luftvägsinflammation, inflammationens svårighetsgrad och dessutom 
visat sig ha ett samband med kroniska förändringar i luftvägarna som utvecklas efter 
längre tids inflammation. Skiktröntgen kan också ge information graden av kroniska 
luftrörsförändringar genom att man värderar de synliga bronkväggsförtjockningarna. 
Resultaten visar att barnen med problematisk svår astma hade högre 
värden av YKL-40 och chitotriosidase jämfört med barnen med kontrollerad astma. 
Bland barnen med terapi resistent astma var det signifikanta korrelationer mellan YKL-
40 och astmakontroll, kväveoxid i utandningsluften, neutrofiler i blod och graden av 
kroniska luftrörsförändringar..  
Detta arbete stödjer att nivåerna av YKL-40 har samband med astmans 
svårighetsgrad även hos barn, och våra fynd indikerar dessutom att YKL-40 har en 
central roll i luftvägsinflammationen eftersom chitinasen är associerat till neutrofil och 
eosinofil luftvägsinflammation, så väl som till kroniska förändringar i luftrören  
Sammanfattningsvis har vi detaljbeskrivit barn med Problematisk svår astma i 
Sverige och identifierat faktorer som kan vara avgörande för utvecklandet av deras 
svåra sjukdom. Vidare, har vi visat på mervärdet av att använda nya metoder inom 
allergidiagnostik. Slutligen är detta avhandlingsarbete ett exempel på nyttan av att ha en 
noggrant karakteriserat patientkohort när man skall utvärdera nya biomarkörer samt att 
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en translationell forskning är nödvändig när man skall undersöka samband mellan 
orsaker, mekanismer och klinisk presentation av komplexa sjukdomar. 
   47 
10 ACKNOWLEDGEMENTS  
  
Many people have contributed to the work undertaken in this thesis. In particular I 
would like to thank the following persons: 
 
First and foremost: All the children participating in this study! 
 
My supervisor, Gunilla Hedlin, for outstanding supervising skills and for having the 
inspiration and commitment required to initiate and follow through all parts of the 
Severe asthma study. I feel privileged to have the opportunity to work with you. 
Christophe Pedroletti, my co-supervisor, for giving me a job when I 
first came to Stockholm, and later on, for presenting me with “an offer you can´t 
refuse” (to start working on the severe asthma study). Your friendly and sharp-minded 
support throughout the different stages of this project has been truly encouraging. 
Barbro Dahlén, my co-supervisor, for sharing knowledge and scientific 
thinking with me and for your support in the assessment of inflammatory biomarkers. I 
hope we can expand our cooperation in future studies. 
Björn Nordlund, for your optimistic and “no problem” attitude, for 
teaching me pediatric respiratory research in a real life setting and for being a great 
colleague and friend. We drove all over Sweden, we worked day and night and we had 
a lot of fun. I´m looking forward to future cooperation. 
Hans Grönlund – my “off the record” supervisor – for providing me 
with the survival skills necessary for being a PhD student at Karolinska Institutet, for 
introducing me to the Swedish “work in sauna” culture, for scientific contributions and 
for generously sharing state of the art and frontline knowledge of molecular 
allergology. 
Sven Erik Dahlén for consolidating a creative and cooperative 
atmosphere at the Centre for Allergy Research, and for your outspoken interest and 
scientific support. To Roelinde Middelveld for much appreciated help with 
administrative tasks related to meetings, applications and travels. 
Anna James for multiple language revisions, for helping us sort out the 
sputum samples, for excellent guidance with the chitinase manuscript and for creative 
lunch-meetings. 
Anna Nopp and S.G.O Johansson for performing the CD-sens analysis 
on children in this study and for irreplaceable support with the preparation of Paper III. 
Marianne van Hage for always showing interest in my work and for 
your encouragements and support with the analysis of results and writing of Paper I- 
III.  
Erik Melén, who back in 2006 first planted the idea of doing research 
within asthma and allergy in my mind, for inspiring conversations, superior feedback 
on my work and scientific contributions. I would also like to thank some of the other 
persons involved in the genetic analyses in this project Cilla Söderhäll, Lovisa 
Reinius and Christina Orsmark Pietras, I look forward to continue working with 
you. 
Joachim Lundahl for cooperation involving the analysis of 
inflammatory biomarkers. Magnus Borres and Annika Önell at Thermo Fisher 
Scientific for your collaboration on the analysis of the allergen components. Åsa 
Wheelock for support with statistical analysis. Elisabeth Henriksson for patiently 
introducing me to laboratory work. Kjell Arne Arntzen for insightful thoughts about 
becoming a researcher and statistical “snap shot” advice. Kjell Alving for advice 
 48 
regarding the analysis of FeNO. Inger Kull for input to Paper I and your scientific 
contributions to Paper II. Marika Gullberg Lidegran for interpreting the CT-images 
and input to manuscripts. Ola Nilsson for performing the IgG analyses. Astri Lang, 
Karin Lödrup Carlsen and Kai Håkon Carlsen at the University of Oslo for fruitful 
discussions and collaborations. Helena Martin, my external mentor for always being 
ready to sort out smaller and bigger life-issues related to research. Bo Magnusson, for 
making it possible to start my PhD studies, while doing my residency in Paediatrics. 
Dr Hargreave† and Dr Nair (the Firestone institute of Respiratory 
Health, Hamilton) and dr Subbarao (Sick Kids, Toronto) for inspirational and 
educational experiences during my research visit at your clinics in 2009. 
Colleagues at the Lung and Allergy department, Astrid Lindgren 
Children´s hospital for kindly sharing their knowledge of pediatric asthma and allergy 
and for interesting discussions at journal clubs: Anders Lindfors, Catarina Almqvist, 
Maria Ingemansson Sten Erik Bergström, Päivi Söderman, Mia Stalberg, Henrik 
Ljungberg, Nora Nilsson, Daiva Helander, Ann Berglind, Wille Zetterquist, 
Awder Mustafa, Lena Hjelte. Furthermore, to the network of pediatric allergists 
working with severe asthma in Sweden for help with developing the research 
protocol and identifying patients for the study. 
  My colleagues at the Neonatal unit, Karolinska University Hospital, 
Solna, in particular Baldvin Jonsson (Head of the department), MireilleVanpee 
(Fellowship director), Marco Bartocci (Clinical supervisor) and Malin Kjellberg 
(schemaläggare) for an understanding and flexible attitude towards the neverending 
struggle that is combining clinical work with research.  
Jan Holt (former head of Department of Pediatrics, Nordland Hospital, 
Bodø) for inspiring me to become a paediatrician, for interesting discussions about 
asthma research and for guiding me through the first memorable years of my pediatric 
training together with Ingebjörg Fagerli (clinical supervisor), Gunhild Helsvig and 
other colleagues in Bodø. 
My parents, Jorunn and Roald, for teaching me the value of 
stubbornness and honest work and my sister and brother, Kristin and Per-Arild, for 
always bringing new perspectives into my life. To my parents in law, Ritva and Pekka, 
for your much appreciated supportive interest in my work. 
My lovely wife, Tiina, for insisting on moving to Stockholm seven years 
ago, for accepting my endless working hours, for encouraging me when needed and for 
being just lovely! And finally to Olga and Arthur, for just being! 
  
   49 
11 FINANCIAL SUPPORT  
 
the Freemason Child House Foundation in Stockholm 
the Konsul Th. C. Bergh’s Foundation 
the Swedish Asthma and Allergy Association´s Research Foundation  
the Centre for Allergy Research at Karolinska Institutet 
the Pediatric Research Foundation of Astrid Lindgren Children´s Hospital 
the Swedish Heart-Lung Foundation  
Karolinska Institutet   
 50 
12 REFERENCES 
 
1 Ebo DG. Basophil activation tests in food allergy. Clin Exp Allergy. 2009; 39: 1115-6. 
2 Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy. 2009; 39: 1652-
8. 
3 Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008; 454: 
445-54. 
4 Haahtela T, Lindholm H, Bjorksten F, Koskenvuo K, Laitinen LA. Prevalence of asthma in 
Finnish young men. BMJ. 1990; 301: 266-8. 
5 Burney PG, Chinn S, Rona RJ. Has the prevalence of asthma increased in children? Evidence 
from the national study of health and growth 1973-86. BMJ. 1990; 300: 1306-10. 
6 Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms 
of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three 
repeat multicountry cross-sectional surveys. Lancet. 2006; 368: 733-43. 
7 Bjerg-Backlund A, Perzanowski MS, Platts-Mills T, Sandstrom T, Lundback B, Ronmark E. 
Asthma during the primary school ages--prevalence, remission and the impact of allergic 
sensitization. Allergy. 2006; 61: 549-55. 
8 Jackson R, Sears MR, Beaglehole R, Rea HH. International trends in asthma mortality: 1970 to 
1985. Chest. 1988; 94: 914-8. 
9 Lanes SF, Birmann B, Raiford D, Walker AM. International trends in sales of inhaled fenoterol, 
all inhaled beta-agonists, and asthma mortality, 1970-1992. J Clin Epidemiol. 1997; 50: 321-8. 
10 Bergstrom SE, Boman G, Eriksson L, et al. Asthma mortality among Swedish children and young 
adults, a 10-year study. Respir Med. 2008; 102: 1335-41. 
11 Busse WW. Asthma diagnosis and treatment: filling in the information gaps. J Allergy Clin 
Immunol. 2011; 128: 740-50. 
12 GINA. Global strategy for asthma management and prevention.  2008. 
13 Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? 
The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170: 836-44. 
14 Lang A, Carlsen KH, Haaland G, et al. Severe asthma in childhood: assessed in 10 year olds in a 
birth cohort study. Allergy. 2008; 63: 1054-60. 
15 Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and 
control. Eur Respir J. 2008; 32: 545-54. 
16 Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF, Jr., Sorkness CA. Classifying 
asthma severity in children: mismatch between symptoms, medication use, and lung function. Am 
J Respir Crit Care Med. 2004; 170: 426-32. 
17 Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy. 2003; 33: 1622-8. 
18 Hedlin G, Bush A, Lodrup Carlsen K, et al. Problematic severe asthma in children, not one 
problem but many: a GA2LEN initiative. Eur Respir J. 2010; 36: 196-201. 
19 Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: 
confirmation by cluster analysis of children in the National Institutes of Health/National Heart, 
Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011; 127: 
382-89 e1-13. 
20 Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and 
adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007; 119: 1156-63. 
21 Nordlund B, Konradsen J, Pedroletti C, Kull I, Hedlin G. The clinical benefit of evaluating health-
related quality-of-life in children with problematic severe asthma. Acta Paediatr. 2011. 
22 Weinmann S, Kamtsiuris P, Henke KD, Wickman M, Jenner A, Wahn U. The costs of atopy and 
asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr 
Allergy Immunol. 2003; 14: 18-26. 
23 Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE. Extent, patterns, and burden of 
uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007; 62: 126-33. 
24 Bush A, Saglani S. Management of severe asthma in children. Lancet. 2010; 376: 814-25. 
25 The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic 
severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir 
J. 2003; 22: 470-7. 
26 Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma 
phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J 
Allergy Clin Immunol. 2007; 119: 405-13. 
   51 
27 Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG. Features of severe asthma in school-age 
children: Atopy and increased exhaled nitric oxide. J Allergy Clin Immunol. 2006; 118: 1218-25. 
28 Bush A, Hedlin G, Carlsen KH, de Benedictis F, Lodrup-Carlsen K, Wilson N. Severe childhood 
asthma: a common international approach? Lancet. 2008; 372: 1019-21. 
29 Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and 
exacerbations: document presented for the World Health Organization Consultation on Severe 
Asthma. J Allergy Clin Immunol. 2010; 126: 926-38. 
30 Fitzpatrick AM, Teague WG. Progressive airflow limitation is a feature of children with severe 
asthma. J Allergy Clin Immunol. 2011; 127: 282-4. 
31 Gupta A, Bazari F, Holloway E, et al. Progression of Paediatric Difficult Asthma Five Years after 
Initial Assessment. Am J Respir Crit Care Med. 2009; 179. 
32 Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin 
Immunol. 2002; 109: 189-94. 
33 Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new 
powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-
controlled trial. J Allergy Clin Immunol. 2000; 105: 1108-16. 
34 Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in 
treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 
1999; 160: 1862-8. 
35 Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides 
more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy 
Clin Immunol. 2000; 106: 1088-95. 
36 Bukstein D, Kraft M, Liu AH, Peters SP. Asthma end points and outcomes: what have we 
learned? J Allergy Clin Immunol. 2006; 118: S1-15. 
37 Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patient-reported endpoints in 
clinical studies. Eur Respir J. 2001; 17: 220-4. 
38 Moy ML, Israel E, Weiss ST, Juniper EF, Dube L, Drazen JM. Clinical predictors of health-
related quality of life depend on asthma severity. Am J Respir Crit Care Med. 2001; 163: 924-9. 
39 O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol 
in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001; 164: 
1392-7. 
40 de Blic J, Tillie-Leblond I, Tonnel AB, Jaubert F, Scheinmann P, Gosset P. Difficult asthma in 
children: an analysis of airway inflammation. J Allergy Clin Immunol. 2004; 113: 94-100. 
41 Jenkins HA, Cherniack R, Szefler SJ, Covar R, Gelfand EW, Spahn JD. A comparison of the 
clinical characteristics of children and adults with severe asthma. Chest. 2003; 124: 1318-24. 
42 Ramsey CD, Celedon JC, Sredl DL, Weiss ST, Cloutier MM. Predictors of disease severity in 
children with asthma in Hartford, Connecticut. Pediatric pulmonology. 2005; 39: 268-75. 
43 Bossley CJ, Saglani S, Kavanagh C, et al. Corticosteroid responsiveness and clinical 
characteristics in childhood difficult asthma. Eur Respir J. 2009; 34: 1052-9. 
44 van Dalen C, Harding E, Parkin J, Cheng S, Pearce N, Douwes J. Suitability of forced expiratory 
volume in 1 second/forced vital capacity vs percentage of predicted forced expiratory volume in 1 
second for the classification of asthma severity in adolescents. Arch Pediatr Adolesc Med. 2008; 
162: 1169-74. 
45 Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 
2006; 118: 551-9; quiz 60-1. 
46 Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge 
testing-1999. This official statement of the American Thoracic Society was adopted by the ATS 
Board of Directors, July 1999. Am J Respir Crit Care Med. 2000; 161: 309-29. 
47 Weiss ST, Van Natta ML, Zeiger RS. Relationship between increased airway responsiveness and 
asthma severity in the childhood asthma management program. Am J Respir Crit Care Med. 2000; 
162: 50-6. 
48 Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in 
bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled 
steroids. Thorax. 1996; 51: 496-502. 
49 Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a 
reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med. 2010; 181: 
1033-41. 
50 Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric 
oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. 
Thorax. 1998; 53: 91-5. 
 52 
51 Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction 
to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161: 1720-45. 
52 Jenkins HA, Cool C, Szefler SJ, et al. Histopathology of severe childhood asthma: a case series. 
Chest. 2003; 124: 32-41. 
53 Welte T (ed). Difficult to treat Severe asthma: European Repiratory Society 2011. 
54 Martinez FD. New insights into the natural history of asthma: primary prevention on the horizon. 
J Allergy Clin Immunol. 2011; 128: 939-45. 
55 Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and 
prevention. J Allergy Clin Immunol. 2011; 128: 1165-74. 
56 Fitzpatrick AM, Brown LA, Holguin F, Teague WG. Levels of nitric oxide oxidation products are 
increased in the epithelial lining fluid of children with persistent asthma. J Allergy Clin Immunol. 
2009; 124: 990-6 e1-9. 
57 Fitzpatrick AM, Teague WG, Holguin F, Yeh M, Brown LA. Airway glutathione homeostasis is 
altered in children with severe asthma: evidence for oxidant stress. J Allergy Clin Immunol. 2009; 
123: 146-52 e8. 
58 Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar macrophage phagocytosis is 
impaired in children with poorly controlled asthma. J Allergy Clin Immunol. 2008; 121: 1372-8, 
78 e1-3. 
59 Just J, Fournier L, Momas I, Zambetti C, Sahraoui F, Grimfeld A. Clinical significance of 
bronchoalveolar eosinophils in childhood asthma. J Allergy Clin Immunol. 2002; 110: 42-4. 
60 Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989; 320: 365-76. 
61 Fitzpatrick AM, Higgins M, Holguin F, Brown LA, Teague WG. The molecular phenotype of 
severe asthma in children. J Allergy Clin Immunol. 2010; 125: 851-57 e18. 
62 Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled 
nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after 
treatment with oral prednisolone. Am J Respir Crit Care Med. 2001; 164: 1376-81. 
63 Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia 
and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012. 
64 Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 
1990; 323: 1033-9. 
65 Bradley BL, Azzawi M, Jacobson M, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, 
and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison 
with biopsy specimens from atopic subjects without asthma and normal control subjects and 
relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol. 1991; 88: 661-74. 
66 Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin Immunol. 
2007; 120: 997-1009; quiz 10-1. 
67 Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway 
remodeling? Current perspectives. J Allergy Clin Immunol. 2011; 128: 439-48; quiz 49-50. 
68 Bousquet J, Chanez P, Lacoste JY, et al. Asthma: a disease remodeling the airways. Allergy. 1992; 
47: 3-11. 
69 Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations 
selectively associated with severe asthma. Am J Respir Crit Care Med. 2003; 167: 1360-8. 
70 Kaminska M, Foley S, Maghni K, et al. Airway remodeling in subjects with severe asthma with or 
without chronic persistent airflow obstruction. J Allergy Clin Immunol. 2009; 124: 45-51 e1-4. 
71 de Blic J, Scheinmann P. The use of imaging techniques for assessing severe childhood asthma. J 
Allergy Clin Immunol. 2007; 119: 808-10. 
72 Marchac V, Emond S, Mamou-Mani T, et al. Thoracic CT in pediatric patients with difficult-to-
treat asthma. AJR Am J Roentgenol. 2002; 179: 1245-52. 
73 Ketai L, Coutsias C, Williamson S, Coutsias V. Thin-section CT evidence of bronchial thickening 
in children with stable asthma: bronchoconstriction or airway remodeling? Acad Radiol. 2001; 8: 
257-64. 
74 Mitsunobu F, Tanizaki Y. The use of computed tomography to assess asthma severity. Curr Opin 
Allergy Clin Immunol. 2005; 5: 85-90. 
75 Kasahara K, Shiba K, Ozawa T, Okuda K, Adachi M. Correlation between the bronchial 
subepithelial layer and whole airway wall thickness in patients with asthma. Thorax. 2002; 57: 
242-6. 
76 Aysola RS, Hoffman EA, Gierada D, et al. Airway remodeling measured by multidetector CT is 
increased in severe asthma and correlates with pathology. Chest. 2008; 134: 1183-91. 
77 Saglani S, Papaioannou G, Khoo L, et al. Can HRCT be used as a marker of airway remodelling 
in children with difficult asthma? Respir Res. 2006; 7: 46. 
   53 
78 de Blic J, Tillie-Leblond I, Emond S, Mahut B, Dang Duy TL, Scheinmann P. High-resolution 
computed tomography scan and airway remodeling in children with severe asthma. J Allergy Clin 
Immunol. 2005; 116: 750-4. 
79 Taylor DR. Using biomarkers in the assessment of airways disease. J Allergy Clin Immunol. 2011; 
128: 927-34; quiz 35-6. 
80 Lex C, Payne DN, Zacharasiewicz A, et al. Sputum induction in children with difficult asthma: 
safety, feasibility, and inflammatory cell pattern. Pediatric pulmonology. 2005; 39: 318-24. 
81 Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil 
counts: a randomised controlled trial. Lancet. 2002; 360: 1715-21. 
82 Fleming L, Wilson N, Regamey N, Bush A. Use of sputum eosinophil counts to guide 
management in children with severe asthma. Thorax. 2012; 67: 193-8. 
83 Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of 
asthmatics. Eur Respir J. 1993; 6: 1368-70. 
84 Strunk RC, Szefler SJ, Phillips BR, et al. Relationship of exhaled nitric oxide to clinical and 
inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003; 112: 883-
92. 
85 Baraldi E, Carra S, Dario C, et al. Effect of natural grass pollen exposure on exhaled nitric oxide 
in asthmatic children. Am J Respir Crit Care Med. 1999; 159: 262-6. 
86 Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased 
nitric oxide in exhaled air of asthmatic patients. Lancet. 1994; 343: 133-5. 
87 Salome CM, Roberts AM, Brown NJ, Dermand J, Marks GB, Woolcock AJ. Exhaled nitric oxide 
measurements in a population sample of young adults. Am J Respir Crit Care Med. 1999; 159: 
911-6. 
88 Malmberg LP, Petays T, Haahtela T, et al. Exhaled nitric oxide in healthy nonatopic school-age 
children: determinants and height-adjusted reference values. Pediatric pulmonology. 2006; 41: 
635-42. 
89 Thurlbeck WM, Haines JR. Bronchial dimensions and stature. Am Rev Respir Dis. 1975; 112: 
142-5. 
90 Bussink AP, Speijer D, Aerts JM, Boot RG. Evolution of mammalian chitinase(-like) members of 
family 18 glycosyl hydrolases. Genetics. 2007; 177: 959-70. 
91 Bargagli E, Olivieri C, Margollicci M, et al. Serum chitotriosidase levels in patients with allergic 
and non-allergic asthma. Respiration. 2010; 79: 437-8. 
92 Chupp GL, Lee CG, Jarjour N, et al. A chitinase-like protein in the lung and circulation of patients 
with severe asthma. N Engl J Med. 2007; 357: 2016-27. 
93 Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in 
inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011; 73: 479-501. 
94 Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of 
asthma, and lung function. N Engl J Med. 2008; 358: 1682-91. 
95 Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited 
enzyme deficiency. J Biol Chem. 1998; 273: 25680-5. 
96 Wolfe R, Carlin JB, Oswald H, Olinsky A, Phelan PD, Robertson CF. Association between 
allergy and asthma from childhood to middle adulthood in an Australian cohort study. Am J 
Respir Crit Care Med. 2000; 162: 2177-81. 
97 Toelle BG, Xuan W, Peat JK, Marks GB. Childhood factors that predict asthma in young 
adulthood. Eur Respir J. 2004; 23: 66-70. 
98 Almqvist C, Wickman M, Perfetti L, et al. Worsening of asthma in children allergic to cats, after 
indirect exposure to cat at school. Am J Respir Crit Care Med. 2001; 163: 694-8. 
99 Burgess JA, Walters EH, Byrnes GB, et al. Childhood allergic rhinitis predicts asthma incidence 
and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007; 120: 863-9. 
100 Thomas M, Kocevar VS, Zhang Q, Yin DD, Price D. Asthma-related health care resource use 
among asthmatic children with and without concomitant allergic rhinitis. Pediatrics. 2005; 115: 
129-34. 
101 Valenta R, Vrtala S, Focke-Tejkl M, et al. Genetically engineered and synthetic allergen 
derivatives: candidates for vaccination against type I allergy. Biol Chem. 1999; 380: 815-24. 
102 Valenta R, Steinberger P, Duchene M, Kraft D. Immunological and structural similarities among 
allergens: prerequisite for a specific and component-based therapy of allergy. Immunol Cell Biol. 
1996; 74: 187-94. 
103 Madhurantakam C, Nilsson OB, Uchtenhagen H, et al. Crystal structure of the dog lipocalin 
allergen Can f 2: implications for cross-reactivity to the cat allergen Fel d 4. J Mol Biol. 2010; 
401: 68-83. 
 54 
104 Saarelainen SA, Kinnunen TT, Buhot C, et al. Immunotherapeutic potential of the 
immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues. Immunology. 
2008; 123: 358-66. 
105 Borres MP, Ebisawa M, Eigenmann PA. Use of allergen components begins a new era in pediatric 
allergology. Pediatr Allergy Immunol. 2011; 22: 454-61. 
106 Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H. The recombinant allergen-
based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp 
Allergy. 1999; 29: 896-904. 
107 Gronlund H, Adedoyin J, Reininger R, et al. Higher immunoglobulin E antibody levels to 
recombinant Fel d 1 in cat-allergic children with asthma compared with rhinoconjunctivitis. Clin 
Exp Allergy. 2008; 38: 1275-81. 
108 Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy. 2010; 40: 1442-60. 
109 Asarnoj A, Moverare R, Ostblom E, et al. IgE to peanut allergen components: relation to peanut 
symptoms and pollen sensitization in 8-year-olds. Allergy. 2010; 65: 1189-95. 
110 Karasuyama H, Obata K, Wada T, Tsujimura Y, Mukai K. Newly appreciated roles for basophils 
in allergy and protective immunity. Allergy. 2011; 66: 1133-41. 
111 Johansson SG, Nopp A, van Hage M, et al. Passive IgE-sensitization by blood transfusion. 
Allergy. 2005; 60: 1192-9. 
112 Nopp A, Johansson SG, Ankerst J, et al. Basophil allergen threshold sensitivity: a useful approach 
to anti-IgE treatment efficacy evaluation. Allergy. 2006; 61: 298-302. 
113 Dahlen B, Nopp A, Johansson SG, Eduards M, Skedinger M, Adedoyin J. Basophil allergen 
threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthma. Clin Exp Allergy. 
2011; 41: 1091-7. 
114 Buhring HJ, Simmons PJ, Pudney M, et al. The monoclonal antibody 97A6 defines a novel 
surface antigen expressed on human basophils and their multipotent and unipotent progenitors. 
Blood. 1999; 94: 2343-56. 
115 Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 
monoclonal antibody 435. J Allergy Clin Immunol. 1991; 88: 328-38. 
116 Frith J, Fleming L, Bossley C, Ullmann N, Bush A. The complexities of defining atopy in severe 
childhood asthma. Clin Exp Allergy. 2011. 
117 Lodrup Carlsen KC, Haland G, Devulapalli CS, et al. Asthma in every fifth child in Oslo, 
Norway: a 10-year follow up of a birth cohort study. Allergy. 2006; 61: 454-60. 
118 Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European 
Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for 
clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180: 59-99. 
119 CDC. BMI Calculator for Child and Teen; . Centers for Disease Control and Prevention. 2007. 
120 Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for 
assessing asthma control. J Allergy Clin Immunol. 2004; 113: 59-65. 
121 Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005; 26: 
319-38. 
122 Polgar G, Weng TR. The functional development of the respiratory system from the period of 
gestation to adulthood. Am Rev Respir Dis. 1979; 120: 625-95. 
123 Nieminen MM, Lahdensuo A, Kellomaeki L, Karvonen J, Muittari A. Methacholine bronchial 
challenge using a dosimeter with controlled tidal breathing. Thorax. 1988; 43: 896-900. 
124 Yan K, Salome C, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. 
Thorax. 1983; 38: 760-5. 
125 O'Connor G, Sparrow D, Taylor D, Segal M, Weiss S. Analysis of dose-response curves to 
methacholine. An approach suitable for population studies. Am Rev Respir Dis. 1987; 136: 1412-
7. 
126 ATS/ERS recommendations for standardized procedures for the online and offline measurement 
of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 
2005; 171: 912-30. 
127 Corbelli R, Bringolf-Isler B, Amacher A, Sasse B, Spycher M, Hammer J. Nasal nitric oxide 
measurements to screen children for primary ciliary dyskinesia. Chest. 2004; 126: 1054-9. 
128 Schoonhoven A, Rudensky B, Elstein D, et al. Monitoring of Gaucher patients with a novel 
chitotriosidase assay. Clin Chim Acta. 2007; 381: 136-9. 
129 Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993; 31: 183-4. 
130 Bhattacharyya N, Jones DT, Hill M, Shapiro NL. The diagnostic accuracy of computed 
tomography in pediatric chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2004; 130: 
1029-32. 
   55 
131 Deschildre A, Beghin L, Salleron J, et al. Home telemonitoring (FEV1) in children with severe 
asthma does not reduce exacerbations. Eur Respir J. 2011. 
132 Porta. A dictionary of epidemiology. In: Porta (ed.). A dictionary of epidemiology. New York: 
Oxford University Press 2008. 
133 Cruz AA, Bousquet PJ. The unbearable cost of severe asthma in underprivileged populations. 
Allergy. 2009; 64: 319-21. 
134 Covar RA, Strunk R, Zeiger RS, et al. Predictors of remitting, periodic, and persistent childhood 
asthma. J Allergy Clin Immunol. 2010; 125: 359-66 e3. 
135 Lang AM, Konradsen J, Carlsen KH, et al. Identifying problematic severe asthma in the 
individual child--does lung function matter? Acta Paediatr. 2010; 99: 404-10. 
136 Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a 
prospective longitudinal birth cohort study. Pediatr Allergy Immunol. 2002; 13 Suppl 15: 11-3. 
137 Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association 
study of asthma. N Engl J Med. 2010; 363: 1211-21. 
138 Wenzel SE, Balzar S, Ampleford E, et al. IL4R alpha mutations are associated with asthma 
exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med. 2007; 175: 570-6. 
139 Lodrup Carlsen KC, Jaakkola JJ, Nafstad P, Carlsen KH. In utero exposure to cigarette smoking 
influences lung function at birth. Eur Respir J. 1997; 10: 1774-9. 
140 Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of 
cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002; 57: 226-30. 
141 Comhair SA, Gaston BM, Ricci KS, et al. Detrimental effects of environmental tobacco smoke in 
relation to asthma severity. PLoS One. 2011; 6: e18574. 
142 Masuda S, Fujisawa T, Katsumata H, Atsuta J, Iguchi K. High prevalence and young onset of 
allergic rhinitis in children with bronchial asthma. Pediatr Allergy Immunol. 2008; 19: 517-22. 
143 Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. J Allergy Clin 
Immunol. 2001; 107: 73-80. 
144 Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-
based study. Lancet. 2008; 372: 1049-57. 
145 Bracken M, Fleming L, Hall P, et al. The importance of nurse-led home visits in the assessment of 
children with problematic asthma. Arch Dis Child. 2009; 94: 780-4. 
146 Good JT, Jr., Kolakowski CA, Groshong SD, Murphy JR, Martin RJ. Refractory asthma: 
importance of bronchoscopy to identify phenotypes and direct therapy. Chest. 2012; 141: 599-
606. 
147 Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on 
late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a 
studies. Lancet. 2007; 370: 1422-31. 
148 Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl 
J Med. 2011; 365: 1088-98. 
149 Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a 
randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184: 1125-32. 
150 in 't Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are 
associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med. 
2000; 161: 1902-6. 
151 Sutherland ER, Martin RJ, Bowler RP, Zhang Y, Rex MD, Kraft M. Physiologic correlates of 
distal lung inflammation in asthma. J Allergy Clin Immunol. 2004; 113: 1046-50. 
152 Liem JJ, Kozyrskyj AL, Cockroft DW, Becker AB. Diagnosing asthma in children: what is the 
role for methacholine bronchoprovocation testing? Pediatric pulmonology. 2008; 43: 481-9. 
153 Siroux V, Oryszczyn MP, Paty E, et al. Relationships of allergic sensitization, total 
immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA Study. Clin 
Exp Allergy. 2003; 33: 746-51. 
154 Carroll WD, Lenney W, Child F, et al. Asthma severity and atopy: how clear is the relationship? 
Arch Dis Child. 2006; 91: 405-9. 
155 Ponsonby AL, Gatenby P, Glasgow N, Mullins R, McDonald T, Hurwitz M. Which clinical 
subgroups within the spectrum of child asthma are attributable to atopy? Chest. 2002; 121: 135-
42. 
156 Piacentini GL, Peroni DG, Bodini A, Boner AL. Exhaled nitric oxide in children with asthma at 
high altitude. J Allergy Clin Immunol. 2007; 120: 1226-7; author reply 27-8. 
157 Boyle RJ, Pedroletti C, Wickman M, et al. Nocturnal temperature controlled laminar airflow for 
treating atopic asthma: a randomised controlled trial. Thorax. 2011. 
 56 
158 Siracusa MC, Saenz SA, Hill DA, et al. TSLP promotes interleukin-3-independent basophil 
haematopoiesis and type 2 inflammation. Nature. 2011; 477: 229-33. 
159 MacGlashan DW, Jr., Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI 
expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. 
J Immunol. 1997; 158: 1438-45. 
160 Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune 
responses. Blood. 2000; 96: 4028-38. 
161 Almqvist C, Larsson PH, Egmar AC, Hedren M, Malmberg P, Wickman M. School as a risk 
environment for children allergic to cats and a site for transfer of cat allergen to homes. J Allergy 
Clin Immunol. 1999; 103: 1012-7. 
162 Glaumann S, Nopp A, Johansson SG, Rudengren M, Borres MP, Nilsson C. Basophil allergen 
threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC in peanut-sensitized children. 
Allergy. 2012; 67: 242-7. 
163 Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new 
therapeutic approaches? J Allergy Clin Immunol. 2011; 128: 495-505. 
164 Di Domenico M, Bisogno A, Polverino M, De Rosa C, Ricci V, Capasso A. Xolair in asthma 
therapy: an overview. Inflamm Allergy Drug Targets. 2011; 10: 2-12. 
165 Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the 
treatment of severe allergic asthma: A clinical experience update. Respir Med. 2009; 103: 1098-
113. 
166 Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided 
pathologically into two inflammatory subtypes with distinct physiologic and clinical 
characteristics. Am J Respir Crit Care Med. 1999; 160: 1001-8. 
167 Tang H, Fang Z, Sun Y, et al. YKL-40 in asthmatic patients, and its correlations with 
exacerbation, eosinophils and immunoglobulin E. Eur Respir J. 2010; 35: 757-60. 
168 Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like lectin, YKL-40, binds 
specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol 
Chem. 2006; 281: 21082-95. 
169 Bara I, Ozier A, Girodet PO, et al. Role of YKL-40 in Bronchial Smooth Muscle Remodeling in 
Asthma. Am J Respir Crit Care Med. 2012. 
170 Lee CG, Dela Cruz CS, Herzog E, Rosenberg SM, Ahangari F, Elias JA. YKL-40, a Chitinase-
like Protein at the Intersection of Inflammation and Remodeling. Am J Respir Crit Care Med. 
2012; 185: 692-4. 
171 Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 
in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009; 206: 1149-66. 
172 Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a 
matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998; 110: 
351-60. 
173 Otsuka K, Matsumoto H, Niimi A, et al. Sputum YKL-40 Levels and Pathophysiology of Asthma 
and Chronic Obstructive Pulmonary Disease. Respiration. 2011. 
174 Cunningham J, Basu K, Tavendale R, Palmer CN, Smith H, Mukhopadhyay S. The CHI3L1 
rs4950928 polymorphism is associated with asthma-related hospital admissions in children and 
young adults. Ann Allergy Asthma Immunol. 2011; 106: 381-6. 
175 Rathcke CN, Holmkvist J, Husmoen LL, et al. Association of polymorphisms of the CHI3L1 gene 
with asthma and atopy: a populations-based study of 6514 Danish adults. PLoS One. 2009; 4: 
e6106. 
176 Sohn MH, Lee JH, Kim KW, et al. Genetic variation in the promoter region of chitinase 3-like 1 is 
associated with atopy. Am J Respir Crit Care Med. 2009; 179: 449-56. 
177 Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the National 
Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 
2012; 185: 356-62. 
178 Castro M, Fain SB, Hoffman EA, Gierada DS, Erzurum SC, Wenzel S. Lung imaging in 
asthmatic patients: the picture is clearer. J Allergy Clin Immunol. 2011; 128: 467-78. 
179 Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major 
subphenotypes of asthma. Am J Respir Crit Care Med. 2009; 180: 388-95. 
180 Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell 
genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci 
U S A. 2007; 104: 15858-63. 
   57 
181 Edlmayr J, Niespodziana K, Linhart B, et al. A combination vaccine for allergy and rhinovirus 
infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the 
major timothy grass pollen allergen Phl p 1. J Immunol. 2009; 182: 6298-306. 
182 Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces 
tolerance after only 3 injections. J Allergy Clin Immunol. 2012. 
183 Gupta A, Sjoukes A, Richards D, et al. Relationship between serum vitamin D, disease severity, 
and airway remodeling in children with asthma. Am J Respir Crit Care Med. 2011; 184: 1342-9. 
 
 
